US20010016575A1

US20010016575A1 - Antisense modulation of human MDM2 expression

Info

Publication number: US20010016575A1
Application number: US09/752,983
Authority: US
Inventors: Loren Miraglia; Pamela Nero; Mark Graham; Brett Monia; Lex Cowsert
Original assignee: Individual
Current assignee: Individual
Priority date: 1998-03-26
Filing date: 2001-01-02
Publication date: 2001-08-23
Also published as: US6184212B1; US20020151511A1; US6238921B1; CA2322773A1; AU3546799A; JP2002508944A; EP1064391A1; EP1064391A4; WO1999049065A1; AU742993B2

Abstract

Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.

Description

This application is a continuation of U.S. patent application No. 09/280,805 filed Mar. 26, 1999 which is a continuation-in-part of U.S. patent application No. 09/048,810 filed Mar. 26, 1998. [0001]

FIELD OF THE INVENTION

This invention relates to compositions and methods for modulating expression of the human mdm2 gene, a naturally present cellular gene implicated in abnormal cell proliferation and tumor formation. This invention is also directed to methods for inhibiting hyperproliferation of cells; these methods can be used diagnostically or therapeutically. Furthermore, this invention is directed to treatment of conditions associated with expression of the human mdm2 gene.

BACKGROUND OF THE INVENTION

Inactivation of tumor suppressor genes leads to unregulated cell proliferation and is a cause of tumorigenesis. In many tumors, the tumor suppressors, p53 or Rb (retinoblastoma) are inactivated. This can occur either by mutations within these genes, or by overexpression of the mdm2 gene. The mdm2 protein physically associates with both p53 and Rb, inhibiting their function. The levels of mdm2 are maintained through a feedback loop mechanism with p53. Overexpression of mdm2 effectively inactivates p53 and promotes cell proliferation.

The role of p53 in apoptosis and tumorigenesis is well-known in the art (see, in general, Canman, C. E. and Kastan, M. B., Adv. Pharmacol., 1997, 41, 429-460). Mdm2 has been shown to regulate p53's apoptotic functions (Chen, J., et al., Mol. Cell Biol., 1996, 16, 2445-2452; Haupt, Y., et al., EMBO J., 1996, 15, 1596-1606). Overexpression of mdm2 protects tumor cells from p53-mediated apoptosis. Thus, mdm2 is an attractive target for cancers associated with altered p53 expression.

Amplification of the mdm2 gene is found in many human cancers, including soft tissue sarcomas, astrocytomas, glioblastomas, breast cancers and non-small cell lung carcinomas. In many blood cancers, overexpression of mdm2 can occur with a normal copy number. This has been attributed to enhanced translation of mdm2 mRNA, which is thought to be related to a distinct 5′-untranslated region (5′-UTR) which causes the transcript to be translated more efficiently than the normal mdm2 transcript. Landers et al., Cancer Res. 57, 3562, (1997).

Several approaches have been used to disrupt the interaction between p53 and mdm2. Small peptide inhibitors, screened from a phage display library, have been shown in ELISA assays to disrupt this interaction [Bottger et al., J. Mol. Biol., 269, 744 (1997)]. Microinjection of an anti-mdm2 antibody targeted to the p53-binding domain of mdm2 increased p53-dependent transcription [Blaydes et al., Oncogene, 14, 1859 (1997)].

A vector-based antisense approach has been used to study the function of mdm2. Using a rhabdomyosarcoma model, Fiddler et al. [ Mol. Cell Biol., 16, 5048 (1996)] demonstrated that amplified mdm2 inhibits the ability of MyoD to function as a transcription factor. Furthermore, expression of full-length antisense mdm2 from a cytomegalovirus promoter-containing vector restores muscle-specific gene expression.

Antisense oligonucleotides have also been useful in understanding the role of mdm2 in regulation of p53. An antisense oligonucleotide directed to the mdm2 start codon allowed cisplatin-induced p53-mediated apoptosis to occur in a cell line overexpressing mdm2 [Kondo et al., Oncogene, 10, 2001 (1995)]. The same oligonucleotide was found to inhibit the expression of P-glycoprotein [Kondo et al., Br. J. Cancer, 74, 1263 (1996)]. P-glycoprotein was shown to be induced by mdm2. Teoh et al [Blood, 90, 1982 (1997)] demonstrated that treatment with an identical mdm2 antisense oligonucleotide or a shorter version within the same region in a tumor cell line decreased DNA synthesis and cell viability and triggered apoptosis.

Chen et al. [ Proc. Natl. Acad. Sci. USA, 95, 195 (1998); WO 99/10486] disclose antisense oligonucleotides targeted to the coding region of mdm2. A reduction in mdm2 RNA and protein levels was seen, and transcriptional activity from a p53-responsive promoter was increased after oligonucleotide treatment of JAR (choriocarcinoma) or SJSA (osteosarcoma) cells.

WO 93/20238 and WO 97/09343 disclose, in general, the use of antisense constructs, antisense oligonucleotides, ribozymes and triplex-forming oligonucleotides to detect or to inhibit expression of mdm2. EP 635068B1, issued Nov. 5, 1997, describes methods of treating in vitro neoplastic cells with an inhibitor of mdm2, and inhibitory compounds, including antisense oligonucleotides and triple-strand forming oligonucleotides.

There remains a long-felt need for improved compositions and methods for inhibiting mdm2 gene expression.

SUMMARY OF THE INVENTION

The present invention provides antisense compounds which are targeted to nucleic acids encoding human mdm2 and are capable of modulating, and preferably, inhibiting mdm2 expression. The present invention also provides chimeric compounds targeted to nucleic acids encoding human mdm2. The antisense compounds of the invention are believed to be useful both diagnostically and therapeutically, and are believed to be particularly useful in the methods of the present invention.

The present invention also comprises methods of inhibiting the expression of human mdm2, particularly the increased expression resulting from amplification of mdm2. These methods are believed to be useful both therapeutically and diagnostically as a consequence of the association between mdm2 expression and hyperproliferation. These methods are also useful as tools, for example, for detecting and determining the role of mdm2 expression in various cell functions and physiological processes and conditions and for diagnosing conditions associated with mdm2 expression.

The present invention also comprises methods of inhibiting hyperproliferation of cells using compounds of the invention. These methods are believed to be useful, for example, in diagnosing mdm2-associated cell hyperproliferation. Methods of treating abnormal proliferative conditions associated with mdm2 are also provided. These methods employ the antisense compounds of the invention. These methods are believed to be useful both therapeutically and as clinical research and diagnostic tools.

DETAILED DESCRIPTION OF THE INVENTION

Tumors often result from genetic changes in cellular regulatory genes. Among the most important of these are the tumor suppressor genes, of which p53 is the most widely studied. Approximately half of all human tumors have a mutation in the p53 gene. This mutation disrupts the ability of the p53 protein to bind to DNA and act as a transcription factor. Hyperproliferation of cells occurs as a result. Another mechanism by which p53 can be inactivated is through overexpression of mdm2, which regulates p53 activity in a feedback loop. The mdm2 protein binds to p53 in its DNA binding region, preventing its activity. Mdm2 is amplified in some human tumors, and this amplification is diagnostic of neoplasia or the potential therefor. Over one third of human sarcomas have elevated mdm2 sequences. Elevated expression may also be involved in other tumors including but not limited to those in which p53 inactivation has been implicated. These include colorectal carcinoma, lung cancer and chronic myelogenous leukemia.

Many abnormal proliferative conditions, particularly hyperproliferative conditions, are believed to be associated with increased mdm2 expression and are, therefore believed to be responsive to inhibition of mdm2 expression. Examples of these hyperproliferative conditions are cancers, psoriasis, blood vessel stenosis (e.g., restenosis or atherosclerosis), and fibrosis, e.g., of the lung or kidney. Increased levels of wild-type or mutated p53 have been found in some cancers (Nagashima, G., et al., Acta Neurochir. (Wein), 1999, 141, 53- 61; Fiedler, A., et al., Langenbecks Arch. Surg., 1998, 383, 269-275). Increased levels of p53 is also associated with resistance of a cancer to a chemotherapeutic drug (Brown, R., et al., Int. J. Cancer, 1993, 55, 678-684). These diseases or conditions may be amenable to treatment by induction of mdm2 expression.

The present invention employs antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding mdm2, ultimately modulating the amount of mdm2 produced. This is accomplished by providing oligonucleotides which specifically hybridize with nucleic acids, preferably mRNA, encoding mdm2.

This relationship between an antisense compound such as an oligonucleotide and its complementary nucleic acid target, to which it hybridizes, is commonly referred to as “antisense”. “Targeting” an oligonucleotide to a chosen nucleic acid target, in the context of this invention, is a multistep process. The process usually begins with identifying a nucleic acid sequence whose function is to be modulated. This may be, as examples, a cellular gene (or mRNA made from the gene) whose expression is associated with a particular disease state, or a foreign nucleic acid from an infectious agent. In the present invention, the target is a nucleic acid encoding mdm2; in other words, a mdm2 gene or RNA expressed from a mdm2 gene. mdm2 mRNA is presently the preferred target. The targeting process also includes determination of a site or sites within the nucleic acid sequence for the antisense interaction to occur such that modulation of gene expression will result.

In accordance with this invention, persons of ordinary skill in the art will understand that messenger RNA includes not only the information to encode a protein using the three letter genetic code, but also associated ribonucleotides which form a region known to such persons as the 5′-untranslated region, the 3′-untranslated region, the 5′ cap region and intron/exon junction ribonucleotides. Thus, oligonucleotides may be formulated in accordance with this invention which are targeted wholly or in part to these associated ribonucleotides as well as to the informational ribonucleotides. The oligonucleotide may therefore be specifically hybridizable with a transcription initiation site region, a translation initiation codon region, a 5′ cap region, an intron/exon junction, coding sequences, a translation termination codon region or sequences in the 5′- or 3′-untranslated region. Since, as is known in the art, the translation initiation codon is typically 5′-AUG (in transcribed mRNA molecules; 5′-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the “AUG codon,” the “start codon” or the “AUG start codon.” A minority of genes have a translation initiation codon having the RNA sequence 5′-GUG, 5′UUG or 5′-CUG, and 5′-AUA, 5′-ACG and 5′-CUG have been shown to function in vivo. Thus, the terms “translation initiation codon” and “start codon” can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, “start codon” and “translation initiation codon” refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding mdm2, regardless of the sequence(s) of such codons. It is also known in the art that a translation termination codon (or “stop codon”) of a gene may have one of three sequences, i.e., 5′-UAA, 5′-UAG and 5′-UGA (the corresponding DNA sequences are 5′-TAA, 5′-TAG and 5′-TGA, respectively). The terms “start codon region” and “translation initiation codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation initiation codon. This region is a preferred target region. Similarly, the terms “stop codon region” and “translation termination codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′1 or 3′) from a translation termination codon. This region is a preferred target region. The open reading frame (ORF) or “coding region,” which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other preferred target regions include the 5′ untranslated region (5′UTR), known in the art to refer to the portion of an mRNA in the 5′ direction from the translation initiation codon, and thus including nucleotides between the 5′ cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene) and the 3′ untranslated region (3′UTR), known in the art to refer to the portion of an mRNA in the 3′ direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3′ end of an mRNA or corresponding nucleotides on the gene). mdm2 is believed to have alternative transcripts which differ in their 5′-UTR regions. The S-mdm2 transcript class is translated approximately 8-fold more efficiently than the L-mdm2 transcripts produced by the constitutive promoter. Landers et al., Cancer Res., 57, 3562 (1997). Accordingly, both the 5′-UTR of the S-mdm transcript and the 5′-UTR of the L-mdm2 transcript are preferred target regions, with the S-mdm2 5′-UTR being more preferred. mRNA splice sites may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions may also be preferred targets.

Once the target site or sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired modulation.

“Hybridization”, in the context of this invention, means hydrogen bonding, also known as Watson-Crick base pairing, between complementary bases, usually on opposite nucleic acid strands or two regions of a nucleic acid strand. Guanine and cytosine are examples of complementary bases which are known to form three hydrogen bonds between them. Adenine and thymine are examples of complementary bases which form two hydrogen bonds between them.

“Specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide.

It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment and, in the case of in vitro assays, under conditions in which the assays are conducted.

Hybridization of antisense oligonucleotides with mRNA interferes with one or more of the normal functions of mRNA. The functions of mRNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in by the RNA.

The overall effect of interference with mRNA function is modulation of mdm2 expression. In the context of this invention “modulation” means either inhibition or stimulation; i.e., either a decrease or increase in expression. This modulation can be measured in ways which are routine in the art, for example by Northern blot assay of mRNA expression as taught in the examples of the instant application or by Western blot or ELISA assay of protein expression, or by an immunoprecipitation assay of protein expression, as taught in the examples of the instant application. Effects on cell proliferation or tumor cell growth can also be measured, as taught in the examples of the instant application.

The antisense compounds of this invention can be used in diagnostics, therapeutics, prophylaxis, and as research reagents and in kits. Since these compounds hybridize to nucleic acids encoding mdm2, sandwich, calorimetric and other assays can easily be constructed to exploit this fact. Furthermore, since the antisense compounds of this invention hybridize specifically to nucleic acids encoding particular isozymes of mdm2, such assays can be devised for screening of cells and tissues for particular mdm2 isozymes. Such assays can be utilized for diagnosis of diseases associated with various mdm2 forms. Provision of means for detecting hybridization of oligonucleotide with a mdm2 gene or mRNA can routinely be accomplished. Such provision may include enzyme conjugation, radiolabelling or any other suitable detection systems. Kits for detecting the presence or absence of mdm2 may also be prepared.

The present invention is also suitable for diagnosing abnormal proliferative states in tissue or other samples from patients suspected of having a hyperproliferative disease such as cancer or psoriasis. The ability of the oligonucleotides of the present invention to inhibit cell proliferation may be employed to diagnose such states. A number of assays may be formulated employing the present invention, which assays will commonly comprise contacting a tissue sample with an antisense compound of the invention under conditions selected to permit detection and, usually, quantitation of such inhibition. In the context of this invention, to “contact” tissues or cells with an antisense compound means to add the compound(s), usually in a liquid carrier, to a cell suspension or tissue sample, either in vitro or ex vivo, or to administer the antisense compound(s) to cells or tissues within an animal. Similarly, the present invention can be used to distinguish mdm2-associated tumors, particularly tumors associated with mdm2α, from tumors having other etiologies, in order that an efficacious treatment regime can be designed.

The antisense compounds of this invention may also be used for research purposes. Thus, the specific hybridization exhibited by oligonucleotides may be used for assays, purifications, cellular product preparations and in other methodologies which may be appreciated by persons of ordinary skill in the art.

In the context of this invention, the term “oligonucleotide” refers to an oligomer or polymer of ribonucleic acid or deoxyribonucleic acid. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent intersugar (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced binding to target and increased stability in the presence of nucleases.

The antisense compounds in accordance with this invention preferably comprise from about 5 to about 50 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30 linked nucleobases (i.e. from about 8 to about 30 nucleosides). As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2′, 3′ or 5′ hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3′ to 5′ phosphodiester linkage.

Specific examples of some preferred modified oligonucleotides envisioned for this invention include those containing phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with phosphorothioates (usually abbreviated in the art as P═S) and those with CH ₂—NH—O—CH₂, CH₂—N(CH₃)—O—CH₂[known as a methylene(methylimino) or MMI backbone], CH₂—O—N(CH₃)—CH₂, CH₂— N(CH₃)—N(CH₃)—CH₂and O—N(CH₃)—CH₂—CH₂backbones, wherein the native phosphodiester (usually abbreviated in the art as P═O) backbone is represented as O—P—O—CH₂). Also preferred are oligonucleotides having morpholino backbone structures (Summerton and Weller, U.S. Pat. No. 5,034,506). Further preferred are oligonucleotides with NR—C(*)—CH₂—CH₂, CH₂—NR— C(*) —CH₂, CH₂—CH₂—NR—C(*), C(*) —NR—CH₂—CH₂and CH₂—C(*) —NR—CH₂backbones, wherein “*” represents O or S (known as amide backbones; DeMesmaeker et al., WO 92/20823, published Nov. 26, 1992). In other preferred embodiments, such as the peptide nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleobases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen et al., Science, 254, 1497 (1991); U.S. Pat. No. 5,539,082). Other preferred modified oligonucleotides may contain one or more substituted sugar moieties comprising one of the following at the 2′ position: OH, SH, SCH₃, F, OCN, OCH₃OCH₃, OCH₃O(CH₂)_nCH₃, O(CH₂)_nNH₂or O(CH₂)_nCH₃where n is from 1 to about 10; C₁to C₁₀lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF₃; OCF₃; O—, S—, or N-alkyl; O—, S—, or N-alkenyl; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. A preferred modification includes 2′-O-methoxyethyl [which can be written as 2′—O—CH₂CH₂OCH₃, and is also known in the art as 2′—O—(2-methoxyethyl) or 2′-methoxyethoxy] [Martin et al., Helv. Chim. Acta, 78, 486 (1995)]. Other preferred modifications include 2′-methoxy (2′—O—CH₃), 2′-propoxy (2′—OCH₂CH₂CH₃), 2′-aminopropoxy (2′—OCH₂CH₂CH₂NH₂) and 2′-fluoro (2′-F). A further preferred modification includes 2′-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂group, also known as 2′-DMAOE, as described in examples hereinbelow. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide and the 5′ position of the 5′ terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.

The oligonucleotides of the invention may additionally or alternatively include nucleobase modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine and 5-methylcytosine, as well as synthetic nucleobases, e.g., 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N ⁶(6-aminohexyl)adenine and 2,6-diaminopurine [Kornberg, A., DNA Replication, 1974, W. H. Freeman & Co., San Francisco, 1974, pp. 75-77; Gebeyehu, G., et al., Nucleic Acids Res., 15, 4513 (1987)]. 5-methylcytosine (5-me-C) is presently a preferred nucleobase, particularly in combination with 2′-O-methoxyethyl modifications.

Another preferred additional or alternative modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more lipophilic moieties which enhance the cellular uptake of the oligonucleotide. Such lipophilic moieties may be linked to an oligonucleotide at several different positions on the oligonucleotide. Some preferred positions include the 3′ position of the sugar of the 3′ terminal nucleotide, the 5′ position of the sugar of the 5′ terminal nucleotide, and the 2′ position of the sugar of any nucleotide. The N ⁶position of a purine nucleobase may also be utilized to link a lipophilic moiety to an oligonucleotide of the invention (Gebeyehu, G., et al., Nucleic Acids Res., 1987, 15, 4513). Such lipophilic moieties include but are not limited to a cholesteryl moiety [Letsinger et al., Proc. Natl. Acad. Sci. USA,, 86, 6553 (1989)], cholic acid [Manoharan et al., Bioorg. Med. Chem. Let., 4, 1053 (1994)], a thioether, e.g., hexyl-S-tritylthiol [Manoharan et al., Ann. N.Y. Acad. Sci., 660, 306 (1992); Manoharan et al., Bioorg. Med. Chem. Let., 3, 2765 (1993)], a thiocholesterol [Oberhauser et al., Nucl. Acids Res., 20, 533 (1992)], an aliphatic chain, e.g., dodecandiol or undecyl residues [Saison-Behmoaras et al., EMBO J., 10, 111 (1991); Kabanov et al., FEES Lett., 259, 327 (1990); Svinarchuk et al., Biochimie., 75, 49(1993)], a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate [Manoharan et al., Tetrahedron Lett., 36, 3651 (1995); Shea et al., Nucl. Acids Res., 18, 3777 (1990)], a polyamine or a polyethylene glycol chain [Manoharan et al., Nucleosides & Nucleotides, 14, 969 (1995)], or adamantane acetic acid [Manoharan et al., Tetrahedron Lett., 36, 3651 (1995)], a palmityl moiety [Mishra et al., Biochim. Biophys. Acta, 1264, 229 (1995)], or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety [Crooke et al., J. Pharmacol. Exp. Ther., 277, 923 (1996)]. Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides, as disclosed in U.S. Pat. No. 5,138,045, No. 5,218,105 and No. 5,459,255, the contents of which are hereby incorporated by reference.

The present invention also includes oligonucleotides which are chimeric oligonucleotides. “Chimeric” oligonucleotides or “chimeras,” in the context of this invention, are oligonucleotides which contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense inhibition of gene expression. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. This RNAse H-mediated cleavage of the RNA target is distinct from the use of ribozymes to cleave nucleic acids. Ribozymes are not comprehended by the present invention.

Examples of chimeric oligonucleotides include but are not limited to “gapmers,” in which three distinct regions are present, normally with a central region flanked by two regions which are chemically equivalent to each other but distinct from the gap. A preferred example of a gapmer is an oligonucleotide in which a central portion (the “gap”) of the oligonucleotide serves as a substrate for RNase H and is preferably composed of 2′-deoxynucleotides, while the flanking portions (the 5′ and 3′ “wings”) are modified to have greater affinity for the target RNA molecule but are unable to support nuclease activity (e.g., 2′-fluoro- or 2′-O-methoxyethyl-substituted). Other chimeras include “wingmers,” also known in the art as “hemimers,” that is, oligonucleotides with two distinct regions. In a preferred example of a wingmer, the 5′ portion of the oligonucleotide serves as a substrate for RNase H and is preferably composed of 2′-deoxynucleotides, whereas the 3′ portion is modified in such a fashion so as to have greater affinity for the target RNA molecule but is unable to support nuclease activity (e.g., 2′-fluoro- or 2′-O-methoxyethyl-substituted), or vice-versa. In one embodiment, the oligonucleotides of the present invention contain a 2′-O-methoxyethyl (2′—O—CH ₂CH₂OCH₃) modification on the sugar moiety of at least one nucleotide. This modification has been shown to increase both affinity of the oligonucleotide for its target and nuclease resistance of the oligonucleotide. According to the invention, one, a plurality, or all of the nucleotide subunits of the oligonucleotides of the invention may bear a 2′-O-methoxyethyl (—O—CH₂CH₂OCH₃) modification. Oligonucleotides comprising a plurality of nucleotide subunits having a 2′-O-methoxyethyl modification can have such a modification on any of the nucleotide subunits within the oligonucleotide, and may be chimeric oligonucleotides. Aside from or in addition to 2′-O-methoxyethyl modifications, oligonucleotides containing other modifications which enhance antisense efficacy, potency or target affinity are also preferred. Chimeric oligonucleotides comprising one or more such modifications are presently preferred. Through use of such modifications, active oligonucleotides have been identified which are shorter than conventional “first generation” oligonucleotides active against mdm2. Oligonucleotides in accordance with this invention are from 5 to 50 nucleotides in length, preferably from about 8 to about 30. In the context of this invention it is understood that this encompasses non-naturally occurring oligomers as hereinbefore described, having from 5 to 50 monomers, preferably from about 8 to about 30.

The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of the routineer. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and 2′-alkoxy or 2′-alkoxyalkoxy derivatives, including 2′-O-methoxyethyl oligonucleotides [Martin, P., Helv. Chim. Acta, 78, 486 (1995)]. It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling, Va.) to synthesize fluorescently labeled, biotinylated or other conjugated oligonucleotides.

The antisense compounds of the present invention include bioequivalent compounds, including pharmaceutically acceptable salts and prodrugs. This is intended to encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of the nucleic acids of the invention and prodrugs of such nucleic acids.

Pharmaceutically acceptable “salts” are physiologically and pharmaceutically acceptable salts of the nucleic acids of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto [see, for example, Berge et al., “Pharmaceutical Salts,” J. of Pharma Sci., 66:1 (1977)].

For oligonucleotides, examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; © salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The oligonucleotides of the invention may additionally or alternatively be prepared to be delivered in a “prodrug” form. The term “prodrug” indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published Dec. 9, 1993.

For therapeutic or prophylactic treatment, oligonucleotides are administered in accordance with this invention. Oligonucleotide compounds of the invention may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, surface active agents, neutral or cationic lipids, lipid complexes, liposomes, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients and the like in addition to the oligonucleotide. Such compositions and formulations are comprehended by the present invention.

Pharmaceutical compositions comprising the oligonucleotides of the present invention may include penetration enhancers in order to enhance the alimentary delivery of the oligonucleotides. Penetration enhancers may be classified as belonging to one of five broad categories, i.e., fatty acids, bile salts, chelating agents, surfactants and non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, 8:91-192; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7:1). One or more penetration enhancers from one or more of these broad categories may be included. Compositions comprising oligonucleotides and penetration enhancers are disclosed in co-pending U.S. patent application Ser. No. 08/886,829 to Teng et al., filed Jul. 1, 1997, which is herein incorporated by reference in its entirety.

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional compatible pharmaceutically-active materials such as, e.g., antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the invention.

Regardless of the method by which the oligonucleotides of the invention are introduced into a patient, colloidal dispersion systems may be used as delivery vehicles to enhance the in vivo stability of the oligonucleotides and/or to target the oligonucleotides to a particular organ, tissue or cell type. Colloidal dispersion systems include, but are not limited to, macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and lipid:oligonucleotide complexes of uncharacterized structure. A preferred colloidal dispersion system is a plurality of liposomes. Liposomes are microscopic spheres having an aqueous core surrounded by one or more outer layers made up of lipids arranged in a bilayer configuration [see, generally, Chonn et al., Current Op. Biotech., 6, 698 (1995)]. Liposomal antisense compositions are prepared according to the disclosure of co-pending U.S. patent application Ser. No. 08/961,469 to Hardee et al., filed Oct. 31, 1997, herein incorporated by reference in its entirety.

The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, pulmonary administration, e.g., by inhalation or insufflation, or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2′-O-methoxyethyl modification are believed to be particularly useful for oral administration. Modes of administering oligonucleotides are disclosed in co-pending U.S. patent application Ser. No. 08/961,469 to Hardee et al., filed Oct. 31, 1997, herein incorporated by reference in its entirety.

Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. In some cases it may be more effective to treat a patient with an oligonucleotide of the invention in conjunction with other traditional therapeutic modalities in order to increase the efficacy of a treatment regimen. In the context of the invention, the term “treatment regimen” is meant to encompass therapeutic, palliative and prophylactic modalities. For example, a patient may be treated with conventional chemotherapeutic agents, particularly those used for tumor and cancer treatment. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide, trimetrexate, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed., pp. 1206-1228, Berkow et al., eds., Rahay, N.J., 1987). When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide).

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC ₅₀s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 μg to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 μg to 100 g per kg of body weight, once or more daily, to once every 20 years.

Thus, in the context of this invention, by “therapeutically effective amount” is meant the amount of the compound which is required to have a therapeutic effect on the treated mammal. This amount, which will be apparent to the skilled artisan, will depend upon the type of mammal, the age and weight of the mammal, the type of disease to be treated, perhaps even the gender of the mammal, and other factors which are routinely taken into consideration when treating a mammal with a disease. A therapeutic effect is assessed in the mammal by measuring the effect of the compound on the disease state in the animal. For example, if the disease to be treated is cancer, therapeutic effects are assessed by measuring the rate of growth or the size of the tumor, or by measuring the production of compounds such as cytokines, production of which is an indication of the progress or regression of the tumor.

The following examples illustrate the present invention and are not intended to limit the same.

EXAMPLES

Example 1

Synthesis of Oligonucleotides

Unmodified oligodeoxynucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine. β-cyanoethyldiisopropyl-phosphoramidites are purchased from Applied Biosystems (Foster City, Calif.). For phosphorothioate oligonucleotides, the standard oxidation bottle was replaced by a 0.2 M solution of [0052] ³H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation cycle wait step was increased to 68 seconds and was followed by the capping step.
2′-methoxy oligonucleotides are synthesized using 2′-methoxy β-cyanoethyldiisopropyl-phosphoramidites (Chemgenes, Needham, Mass.) and the standard cycle for unmodified oligonucleotides, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds. Other 2′-alkoxy oligonucleotides were synthesized by a modification of this method, using appropriate 2′-modified amidites such as those available from Glen Research, Inc., Sterling, Va. [0053]
2′-fluoro oligonucleotides were synthesized as described in Kawasaki et al., [0054] J. Med. Chem., 36, 831 (1993). Briefly, the protected nucleoside N⁶-benzoyl-2′-deoxy-2′-fluoroadenosine was synthesized utilizing commercially available 9-β-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2′-α-fluoro atom is introduced by a S_N2-displacement of a 2′-β-O-trifyl group. Thus N⁶-benzoyl-9-β-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3′,5′-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N⁶-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5′-dimethoxytrityl-(DMT) and 5′-DMT-3′-phosphoramidite intermediates.
The synthesis of 2′-deoxy-2′-fluoroguanosine was accomplished using tetraisopropyldisiloxanyl (TPDS) protected 9-β-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5′-DMT- and 5′-DMT-3′-phosphoramidites. [0055]
Synthesis of 2′-deoxy-2′-fluorouridine was accomplished by the modification of a known procedure in which 2, 2′-anhydro-1-β-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5′-DMT and 5′-DMT-3′phosphoramidites. [0056]
2′-deoxy-2′-fluorocytidine was synthesized via amination of 2′-deoxy-2′-fluorouridine, followed by selective protection to give N[0057] ⁴-benzoyl-2′-deoxy-2′-fluorocytidine. Standard procedures were used to obtain the 5′-DMT and 5′-DMT-3′phosphoramidites.
2′-(2-methoxyethyl)-modified amidites are synthesized according to Martin, P., [0058] Helv. Chim. Acta, 78,486 (1995). For ease of synthesis, the last nucleotide was a deoxynucleotide. 2′—O—CH₂CH₂OCH₃-cytosines may be 5-methyl cytosines.

Synthesis of 5-Methyl Cytosine Monomers

2,2′-Anhydro[1-(β-D-arabinofuranosyl)-5-methyluridine]: [0059]
5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenyl-carbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60° C. at 1 mm Hg for 24 hours) to give a solid which was crushed to a light tan powder (57 g, 85% crude yield). The material was used as is for further reactions. [0060]

2′-O-Methoxyethyl-5-methyluridine

2,2′-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160° C. After heating for 48 hours at 155-160° C., the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH[0061] ₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂(250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product.

2-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine

2′-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxy-trityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH[0062] ₃CN (200 mL). The residue was dissolved in CHCl₃(1.5 L) and extracted with 2×500 mL of saturated NaHCO₃and 2×500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/-Hexane/Acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

3′-O-Acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyl-uridine

2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by tlc by first quenching the tlc sample with the addition of MeOH. Upon completion of the reaction, as judged by tlc, MeOH (50 mL) was added and the mixture evaporated at 35° C. The residue was dissolved in CHCl[0063] ₃(800 mL) and extracted with 2×200 mL of saturated sodium bicarbonate and 2×200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane (4:1). Pure product fractions were evaporated to yield 96 g (84%).

3′-O-Acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3′-O-acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH[0064] ₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to −5° C. and stirred for 0.5 h using an overhead stirrer. POCl₃was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10° C., and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the later solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1×300 mL of NaHCO₃and 2×300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine

A solution of 3′-O-acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH[0065] ₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2×200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃gas was added and the vessel heated to 100° C. for 2 hours (tlc showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N⁴-Benzoyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyl-cytidine

2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tlc showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl[0066] ₃(700 mL) and extracted with saturated NaHCO₃(2×300 mL) and saturated NaCl (2×300 mL), dried over MgSO₄and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/Hexane (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N⁴-Benzoyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine-3′-amidite

N[0067] ⁴-Benzoyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂(1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (tlc showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃(1×300 mL) and saturated NaCl (3×300 mL). The aqueous washes were back-extracted with CH₂Cl₂(300 mL) , and the extracts were combined, dried over MgSO₄and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc\Hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.
5-methyl-2′-deoxycytidine (5-me-C) containing oligonucleotides were synthesized according to published methods [Sanghvi et al., [0068] Nucl. Acids Res., 21, 3197 (1993)] using commercially available phosphoramidites (Glen Research, Sterling, Va. or ChemGenes, Needham, Mass.).

2′-O-(dimethylaminooxyethyl) Nucleoside Amidites

2′-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2′-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine. [0069]

5′-O-tert-Butyldiphenylsilyl-O²-2′-anhydro-5-methyluridine

O[0070] ²-2′-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0 g, 0.416 mmol), dimethylaminopyridine (0.66 g, 0.013 eq, 0.0054 mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8 g, 119.0 mL, 1.1 eq, 0.458 mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2×1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600 mL) and the solution was cooled to −10° C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3×200 mL) and dried (40° C., 1 mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5′-O-tert-Butyldiphenylsilyl-2′-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5′-O-tert-Butyldiphenylsilyl-O[0071] ²-2′-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160° C. was reached and then maintained for 16 h (pressure<100 psig) . The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1 mm Hg) in a warm water bath (40-100° C.) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2 kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84 g, 50%), contaminated starting material (17.4 g) and pure reusable starting material 20 g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine

5′-O-tert-Butyldiphenylsilyl-2′-O-(2-hydroxyethyl)-5-methyluridine (20 g, 36.98 mmol) was mixed with triphenylphosphine (11.63 g, 44.36 mmol) and N-hydroxyphthalimide (7.24 g, 44.36 mmol). It was then dried over P[0072] ₂O₅under high vacuum for two days at 40° C. The reaction mixture was flushed with argon and dry THF (369.8 mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98 mL, 44.36 mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819, 86%).

5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine (3.1 g, 4.5 mmol) was dissolved in dry CH[0073] ₂Cl₂(4.5 mL) and methylhydrazine (300 mL, 4.64 mmol) was added dropwise at −10° C. to 0° C. After 1 hr the mixture was filtered, the filtrate was washed with ice cold CH₂Cl₂and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2′-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5 mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eg.) was added and the mixture for 1 hr. Solvent was removed under vacuum; residue chromatographed to get 5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95, 78%).

5′-O-tert-Butyldiphenylsilyl-2′-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77 g, 3.12 mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6 mL). Sodium cyanoborohydride (0.39 g, 6.13 mmol) was added to this solution at 10° C. under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10° C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 hr, the reaction monitored by TLC (5% MeOH in CH[0074] ₂Cl₂). Aqueous NaHCO₃solution (5%, 10 mL) was added and extracted with ethyl acetate (2×20 mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6 mL) . Formaldehyde (20% w/w, 30 mL, 3.37 mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10° C. in an ice bath, sodium cyanoborohydride (0.39 g, 6.13 mmol) was added and reaction mixture stirred at 10° C. for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃(25 mL) solution was added and extracted with ethyl acetate (2×25 mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂to get 5′-O-tert-butyldiphenylsilyl-2′-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6 g, 80%).

2′-O-(dimethylaminooxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91 mL, 24.0 mmol) was dissolved in dry THF and triethylamine (1.67 mL, 12 mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5′-O-tert-butyldiphenylsilyl-2′-O-[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40 g, 2.4 mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH[0075] ₂Cl₂) Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂to get 2′-O-(dimethylaminooxyethyl)-5-methyluridine (766 mg, 92.5%).

5′-O-DMT-2′-O-(dimethylaminooxyethyl)-5-methyluridine

2′-O-(dimethylaminooxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P[0076] ₂O₅under high vacuum overnight at 40° C. It was then co-evaporated with anhydrous pyridine (20 mL). The residue obtained was dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol), 4,4′-dimethoxytrityl chloride (880 mg, 2.60 mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH₂Cl₂(containing a few drops of pyridine) to get 5′-O-DMT-2′-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13 g, 80%).

5′-O-DMT-2′-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5′-O-DMT-2′-O-(dimethylaminooxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL). To the residue N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and dried over P[0077] ₂O₅under high vacuum overnight at 40° C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70 mL) and washed with 5% aqueous NaHCO₃(40 mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5′-O-DMT-2′-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04 g, 74.9%).

2′-(Aminooxyethoxy) Nucleoside Amidites

2′-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2′-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly. [0078]

N2-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2′-O-aminooxyethyl guanosine analog may be obtained by selective 2′-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2′-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3′-O-isomer. 2′-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2′-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxy trityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2′-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl) guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine-3′-[ (2-cyanoethyl)-N,N-diisopropylphosphoramidite]. [0079]
Oligonucleotides having methylene (methylimino) (MMI) backbones are synthesized according to U.S. Pat. No. 5,378,825, which is coassigned to the assignee of the present invention and is incorporated herein in its entirety. For ease of synthesis, various nucleoside dimers containing MMI linkages were synthesized and incorporated into oligonucleotides. Other nitrogen-containing backbones are synthesized according to WO 92/20823 which is also coassigned to the assignee of the present invention and incorporated herein in its entirety. [0080]
Oligonucleotides having amide backbones are synthesized according to De Mesmaeker et al., [0081] Acc. Chem. Res., 28, 366 (1995). The amide moiety is readily accessible by simple and well-known synthetic methods and is compatible with the conditions required for solid phase synthesis of oligonucleotides.
Oligonucleotides with morpholino backbones are synthesized according to U.S. Pat. No. 5,034,506 (Summerton and Weller). [0082]
Peptide-nucleic acid (PNA) oligomers are synthesized according to P. E. Nielsen et al., [0083] Science, 254, 1497 (1991).
After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55° C. for 18 hours, the oligonucleotides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by [0084] ³¹p nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., J. Biol. Chem., 266, 18162 (1991). Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 2

Human mdm2 Oligonucleotide Sequences

The oligonucleotides tested are presented in Table 1. Sequence data are from the cDNA sequence published by Oliner, J. D., et al., [0085] Nature, 358, 80 (1992); Genbank accession number Z12020, provided herein as SEQ ID NO: 1. Oligonucleotides were synthesized primarily as chimeric oligonucleotides having a centered deoxy gap of eight nucleotides flanked by 2′-O-methoxyethyl regions.
A549 human lung carcinoma cells (American Type Culture Collection, Manassas, Va.) were routinely passaged at 80-90% confluency in Dulbecco's modified Eagle's medium (DMEM) and 10% fetal bovine serum (Hyclone, Logan, Utah). JEG-3 cells, a human choriocarcinoma cell line (American Type Culture Collection, Manassas, Va.), were maintained in RPMI1640, supplemented with 10% fetal calf serum. All cell culture reagents, except as otherwise indicated, are obtained from Life Technologies (Rockville, Md.). [0086]

A549 cells were treated with phosphorothioate oligonucleotides at 200 nM for four hours in the presence of 6 μg/ml LIPOFECTIN™, washed and allowed to recover for an additional 20 hours. Total RNA was extracted and 15-20 μg of each was resolved on 1% gels and transferred to nylon membranes. The blots were probed with a ³²p radiolabeled mdm2 cDNA probe and then stripped and reprobed with a radiolabeled G3PDH probe to confirm equal RNA loading. mdm2 transcripts were examined and quantified with a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.). Results are shown in Table 2. Oligonucleotides 16506 (SEQ ID NO: 3), 16507 (SEQ ID NO: 4), 16508 (SEQ ID NO: 5), 16510 (SEQ ID NO: 7), 16518 (SEQ ID NO: 15), 16520 (SEQ ID NO: 17), 16521 (SEQ ID NO: 18), 16522 (SEQ ID NO: 19) and 16524 (SEQ ID NO: 21) gave at least approximately 50% reduction of mdm2 mRNA levels. Oligonucleotides 16507 and 16518 gave better than 85% reduction of mdm2.

TABLE 1


Nucleotide Sequences of Human mdm2
Phosphorothioate Oligonucleotides

		SEQ	TARGET GENE	GENE
ISIS	NUCLEOTIDE SEQUENCE¹	ID	NUCLEOTIDE	TARGET
NO.	(5′ -> 3′)	NO:	CO-ORDINATES²	REGION

16506	CAGCCAAGCTCGCGCGGTGC	3	0001-0020	5′-UTR
16507	TCTTTCCGACACACAGGGCC	4	0037-0056	5′-UTR
16508	CAGCAGGATCTCGGTCAGAG	5	0095-0114	5′-UTR
16509	GGGCGCTCGTACGCACTAAT	6	0147-0166	5′-UTR
16510	TCGGGGATCATTCCACTCTC	7	0181-0200	5′-UTR
16511	CGGGGTTTTCGCGCTTGGAG	8	0273-0292	5′-UTR
16512	CATTTGCCTGCTCCTCACCA	9	0295-0314	AUG
16513	GTATTGCACATTTGCCTGCT	10	0303-0322	AUG
16514	AGCACCATCAGTAGGTACAG	11	0331-0350	ORF
16515	CTACCAAGTTCCTGTAGATC	12	0617-0636	ORF
16516	TCAACTTCAAATTCTACACT	13	1047-1066	ORF
16517	TTTACAATCAGGAACATCAA	14	1381-1400	ORF
16518	AGCTTCTTTGCACATGTAAA	15	1695-1714	ORF
16519	CAGGTCAACTAGGGGAAATA	16	1776-1795	stop
16520	TCTTATAGACAGGTCAACTA	17	1785-1804	stop
16521	TCCTAGGGTTATATAGTTAG	18	1818-1837	3′-UTR
16522	AAGTATTCACTATTCCACTA	19	1934-1953	3′-UTR
16523	CCAAGATCACCCACTGCACT	20	2132-2151	3′-UTR
16524	AGGTGTGGTGGCAGATGACT	21	2224-2243	3′-UTR
16525	CCTGTCTCTACTAAAAGTAC	22	2256-2275	3′-UTR
17604	ACAAGCCTTCGCTCTACCGG	23	scrambled	16507
			control
17605	TTCAGCGCATTTGTACATAA	24	scrambled	16518
			control
17615	TCTTTCCGACACACAGGGCC	25	0037-0056	5′-UTR
17616	AGCTTCTTTGCACATGTAAA	15	1695-1714	ORF
17755	AGCTTCTTTGCACATGTAAA	15	1695-1714	ORF
17756	AGCTTCTTTATACATGTAAA	26	2-base	17616
			mismatch
17757	AGCTTCTTTACACATGTAAA	27	1-base	17616
			mismatch



# 267-286 on the Landers sequence.

TABLE 2


Activities of Phosphorothioate Oligonucleotides Targeted to
Human mdm2

	SEQ	GENE
ISIS	ID	TARGET	% mRNA	% mRNA
No:	NO:	REGION	EXPRESSION	INHIBITION

LIPOFECTIN ™	—	—	100%	0%
only
16506	3	5′-UTR	45%	55%
16507	4	5′-UTR	13%	87%
16508	5	5′-UTR	38%	62%
16509	6	5′-UTR	161%	—
16510	7	5′-UTR	46%	54%
16511	8	5′-UTR	91%	9%
16512	9	AUG	89%	11%
16513	10	AUG	174%	—
16514	11	Coding	92%	8%
16515	12	Coding	155%	—
16516	13	Coding	144%	—
16517	14	Coding	94%	6%
16518	15	Coding	8%	92%
16519	16	stop	73%	27%
16520	17	stop	51%	49%
16521	18	3′-UTR	38%	62%
16522	19	3′-UTR	49%	51%
16523	20	3′-UTR	109%	—
16524	21	3′-UTR	47%	53%
16525	22	3′-UTR	100%	—

Example 3

Dose Response of Antisense Oligonucleotide Effects on Human mdm2 mRNA Levels in A549 Cells

Oligonucleotides 16507 and 16518 were tested at different concentrations. A549 cells were grown, treated and processed as described in Example 2. LIPOFECTIN™ was added at a ratio of 3 μg/ml per 100 nM of oligonucleotide. The control included LIPOFECTINT™ at a concentration of 12 μg/ml. Oligonucleotide 17605, an oligonucleotide with different sequence but identical base composition to oligonucleotide 16518, was used as a negative control. Results are shown in Table 3. Oligonucleotides 16507 and 16518 gave approximately 90% inhibition at concentrations greater than 200 nM. No inhibition was seen with oligonucleotide 17605.

TABLE 3


Dose Response of A549 Cells to mdm2
Antisense Oligonucleotides (ASOs)

	SEQ			% mRNA	% mRNA
	ID	ASO Gene		Ex-	In-
ISIS #	NO:	Target	Dose	pression	hibition

control	—	LIPOFECTIN ™	—	100%	0%
		only
16507	4	5′-UTR	25 nM	55%	45%
16507	4	″	50 nM	52%	48%
16507	4	″	100 nM	24%	76%
16507	4	″	200 nM	12%	88%
16518	15	Coding	50 nM	18%	82%
16518	15	″	100 nM	14%	86%
16518	15	″	200 nM	9%	91%
16518	15	″	400 nM	8%	92%
17605	24	scrambled	400 nM	129%	—

Example 4

Time Course of Antisense Oligonucleotide Effects on Human mdm2 mRNA Levels in A549 Cells

Oligonucleotides 16507 and 17605 were tested by treating for varying times. A549 cells were grown, treated for times indicated in Table 4 and processed as described in Example 2. Results are shown in Table 4. Oligonucleotide 16507 gave greater than 90% inhibition throughout the time course. No inhibition was seen with oligonucleotide 17605.

TABLE 4


Time Course of Response of Cells to
Human mdm2 Antisense Oligonucleotides (ASOs)

	SEQ	ASO Gene		% RNA	% RNA
	ID	Target		Ex-	In-
ISIS #	NO:	Region	Time	pression	hibition

basal	—	LIPOFECTIN ™	24 h	100%	0%
		only
basal	—	LIPOFECTIN ™	48 h	100%	0%
		only
basal	—	LIPOFECTIN ™	72 h	100%	0%
		only
16518	15	Coding	24 h	3%	97%
16518	15	″	48 h	6%	94%
16518	15	″	72 h	5%	95%
17605	24	scrambled	24 h	195%	—
17605	24	″	48 h	100%	—
17605	24	″	72 h	102%	—

Example 5

Effect of Antisense Oligonucleotides on Cell Proliferation in A549 Cells

A549 cells were treated on day 0 for four hours with 400 nM oligonucleotide and 12 mg/ml LIPOFECTIN. After four hours, the medium was replaced. Twenty-four, forty-eight or seventy-two hours after initiation of oligonucleotide treatment, live cells were counted on a hemacytometer. Results are shown in Table 5.

TABLE 5


Antisense Inhibition of Cell Proliferation
in A549 cells

	SEQ	ASO Gene
	ID	Target		% Cell	% Growth
ISIS #	NO:	Region	Time	Growth	Inhibition

basal	—	LIPOFECTIN ™	24 h	100%	0%
		only
basal	—	LIPOFECTIN ™	48 h	100%	0%
		only
basal	—	LIPOFECTIN ™	72 h	100%	0%
		only
16518	15	Coding	24 h	53%	47%
16518	15	″	48 h	27%	73%
16518	15	″	72 h	17%	83%
17605	24	scrambled	24 h	93%	7%
17605	24	″	48 h	76%	24%
17605	24	″	72 h	95%	5%

Example 6

Effect of mdm2 Antisense Oligonucleotide on p53 Protein Levels

JEG3 cells were cultured and treated as described in Example 2, except that 300 nM oligonucleotide and 9 μg/ml of LIPOFECTIN™ was used. [0092]
For determination of p53 protein levels by western blot, cellular extracts were prepared using 300 μl of RIPA extraction buffer per 100-mm dish. The protein concentration was quantified by Bradford assay using the BioRad kit (BioRad, Hercules, Calif.). Equal amounts of protein were loaded on 10% or 12% SDS-PAGE mini-gel (Novex, San Diego, Calif.). Once transferred to PVDF membranes (Millipore, Bedford, Mass.), the membranes were then treated for a minimum of 2h with specific primary antibody (p53 antibody, Transduction Laboratories, Lexington, Ky.) followed by incubation with secondary antibody conjugated to HRP. The results were visualized by ECL Plus Western Blotting Detection System (Amersham Pharmacia Biotech, Piscataway, N.J.). In some experiments, the blots were stripped in stripping buffer (2% SDS, 12.5 mM Tris, pH 6.8) for 30 min. at 50° C. After extensive washing, the blots were blocked and blotted with different primary antibody. [0093]
Results are shown in Table 6. Treatment with mdm2 antisense oligonucleotide results in the induction of p53 levels. An approximately three-fold increase in activity was seen under these conditions. [0094]

TABLE 6

Activity of ISIS 16518 on p53 Protein Levels

GENE

ISIS SEQ ID TARGET % protein

No: NO: REGION EXPRESSION

LIPOFECTIN ™ only — — 100%

16518 15 coding 289%

Example 7

Effect of ISIS 16518 on Expression of p53 Mediated Genes

p53 is known to regulate the expression of a number of genes and to be involved in apoptosis. Representative genes known to be regulated by p53 include p21 (Deng, C., et al., [0095] Cell, 1995, 82, 675), bax (Selvakumaran, M., et al., Oncogene, 1994, 9, 1791-1798) and GADD45 (Carrier, F., et al., J. Biol. Chem., 1994, 269, 32672-32677). The effect of an mdm2 antisense oligonucleotide on these genes is investigated by RPA analysis using the RIBOQUANT™ RPA kit, according to the manufacturer's instructions (Pharmingen, San Diego, Calif.), along with the hSTRESS-1 multi-probe template set. Included in this template set are bclx, p53, GADD45, c-fos, p21, bax, bcl2 and mcl1. The effect of mdm2 antisense oligonucleotides on p53-mediated apoptosis can readily be assessed using commercial kits based on apoptotic markers such as DNA fragmentation or caspase activity.

Example 8

Additional Human mdm2 Chimeric (Deoxy Gapped) Antisense Oligonucleotides

Additional oligonucleotides targeted to the 5′-untranslated region of human mdm2 mRNA were designed and synthesized. Sequence data are from the cDNA sequence published by Zauberman, A., et al., Nucleic Acids Res., 23, 2584 (1995); Genbank accession number HSU28935. Oligonucleotides were synthesized primarily as chimeric oligonucleotides having a centered deoxy gap of eight nucleotides flanked by 2′-O-methoxyethyl regions. The oligonucleotide sequences are shown in Table 7. These oligonucleotides were tested in A549 cells as described in Example 2. Results are shown in Table 8.

TABLE 7


Nucleotide Sequences of additional Human mdm2
Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides

21926	CTACCCTCCAATCGCCACTG	28	0238-0257	coding
21927	GGTCTACCCTCCAATCGCCA	29	0241-0260	coding
21928	CGTGCCCACAGGTCTACCCT	30	0251-0270	coding
21929	AAGTGGCGTGCGTCCGTGCC	31	0265-0284	coding
21930	AAAGTGGCGTGCGTCCGTGC	32	0266-0285	coding

[0097]

TABLE 8

Activities of Chimeric (deoxy gapped) Oligonucleotides

Targeted to Human mdm2

SEQ GENE

ISIS ID TARGET % mRNA % mRNA

No: NO: REGION EXPRESSION INHIBITION

LIPOFECTIN ™ — — 100% 0%

only

21926 28 coding 345% —

21927 29 coding 500% —

21928 30 coding 417% —

21929 31 coding 61% 39%

21930 32 coding 69% 31%
These oligonucleotide sequences were also tested for their ability to reduce mdm2 protein levels. JEG3 cells were cultured and treated as described in Example 2, except that 300 nM oligonucleotide and 9 μg/ml of LIPOFECTIN™ was used. Mdm2 protein levels were assayed by Western blotting as described in Example 6, except an mouse anti-mdm2 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.) was used. Results are shown in Table 9. [0098]

TABLE 9

Activities of Chimeric (deoxy gapped) Human mdm2 Antisense

Oligonucleotides on mdm2 Protein Levels

SEQ GENE

ISIS ID TARGET % PROTEIN % PROTEIN

No: NO: REGION EXPRESSION INHIBITION

LIPOFECTIN ™ — — 100% 0%

only

21926 28 coding 30% 70%

21927 29 coding 18% 82%

21928 30 coding 43% 57%

21929 31 coding 62% 38%

21930 32 coding 56% 44%
Each oligonucleotide tested reduced mdm2 protein levels by greater than approximately 40%. Maximum inhibition was seen with oligonucleotide 21927 (SEQ ID NO. 29) which gave greater than 80% inhibition of mdm2 protein. [0099]

Example 9

Additional Human mdm2 Antisense Oligonucleotides

Additional oligonucleotides targeted to human mdm2 mRNA were designed and synthesized. Sequence data are from the cDNA sequence published by Zauberman, A., et al., [0100] Nucleic Acids Res., 23, 2584 (1995); Genbank accession number HSU28935. Oligonucleotides were synthesized in 96 well plate format via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-di-isopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, Calif., or Pharmacia, Piscataway, N.J.). Non-standard nucleosides are synthesized as per published methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.
Oligonucleotides were cleaved from support and deprotected with concentrated NH[0101] ₄OH at elevated temperature (55-60° C.) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.
Two sets of oligonucleotides were synthesized; one as phosphorothioate oligodeoxynucleotides, the other as chimeric oligonucleotides having a centered deoxy gap of ten nucleotides flanked by regions of five 2′-O-methoxyethyl nucleotides. These oligonucleotides sequences are shown in Tables 10 and 11. [0102]

mRNA was isolated using the RNAEASY® kit (Qiagen, Santa Clarita, Calif.).

TABLE 10


Nucleotide Sequences of Human mdm2
Phosphorothioate Oligodeoxynucleotides

31393	CAGCCAAGCTCGCGCGGTGC	3	0001-0020	5′ UTR
31712	AAGCAGCCAAGCTCGCGCGG	33	0004-0023	5′ UTR
31552	CAGGCCCCAGAAGCAGCCAA	34	0014-0033	5′ UTR
31713	GCCACACAGGCCCCAGAAGC	35	0020-0039	5′ UTR
31394	ACACACAGGGCCACACAGGC	36	0029-0048	5′ UTR
31714	TTCCGACACACAGGGCCACA	37	0034-0053	5′ UTR
31553	GCTCCATCTTTCCGACACAC	38	0043-0062	5′ UTR
31715	GCTTCTTGCTCCATCTTTCC	39	0050-0069	5′ UTR
31395	CCCTCGGGCTCGGCTTCTTG	40	0062-0081	5′ UTR
31716	GCGGCCGCCCCTCGGGCTCG	41	0070-0089	5′ UTR
31554	AAGCAGCAGGATCTCGGTCA	42	0098-0107	5′ UTR
31717	GCTGCGAAAGCAGCAGGATC	43	0105-0124	5′ UTR
31396	TGCTCCTGGCTGCGAAAGCA	44	0113-0132	5′ UTR
31718	GGGACGGTGCTCCTGGCTGC	45	0120-0139	5′ UTR
31555	ACTGGGCGCTCGTACGCACT	46	0150-0169	5′ UTR
31719	GCCAGGGCACTGGGCGCTCG	47	0158-0177	5′-UTR
31397	TCTCCGGGCCAGGGCACTGG	48	0165-0184	5′ UTR
31720	TCATTCCACTCTCCGGGCCA	49	0174-0193	5′ UTR
31556	GGAAGCACGACGCCCTGGGC	50	0202-0221	5′ UTR
31721	TACTGCGGAAGCACGACGCC	51	0208-0227	5′ UTR
31398	GGGACTGACTACTGCGGAAG	52	0217-0236	5′ UTR
31722	TCAAGACTCCCCAGTTTCCT	53	0242-0261	5′ UTR
31557	CCTGCTCCTCACCATCCGGG	54	0289-0308	5′ UTR
31399	TTTGCCTGCTCCTCACCATC	55	0293-0312	AUG
31400	ATTTGCCTGCTCCTCACCAT	56	0294-0313	AUG
31401	CATTTGCCTGCTCCTCACCA	9	0295-0314	AUG
31402	ACATTTGCCTGCTCCTCACC	57	0296-0315	AUG
31403	CACATTTGCCTGCTCCTCAC	58	0297-0316	AUG
31404	GCACATTTGCCTGCTCCTCA	59	0298-0317	AUG
31405	TGCACATTTGCCTGCTCCTC	60	0299-0318	AUG
31406	TTGCACATTTGCCTGCTCCT	61	0300-0319	AUG
31407	ATTGCACATTTGCCTGCTCC	62	0301-0320	AUG
31408	TATTGCACATTTGCCTGCTC	63	0302-0321	AUG
31409	GTATTGCACATTTGCCTGCT	10	0303-0322	AUG
31410	GGTATTGCACATTTGCCTGC	64	0304-0323	AUG
31411	TGGTATTGCACATTTGCCTG	65	0305-0324	AUG
31412	TTGGTATTGCACATTTGCCT	66	0306-0325	AUG
31413	GTTGGTATTGCACATTTGCC	67	0307-0326	AUG
31414	TGTTGGTATTGCACATTTGC	68	0308-0327	AUG
31415	ATGTTGGTATTGCACATTTG	69	0309-0328	AUG
31416	CATGTTGGTATTGCACATTT	70	0310-0329	AUG
31417	ACATGTTGGTATTGCACATT	71	0311-0330	AUG
31418	GACATGTTGGTATTGCACAT	72	0312-0331	AUG
31419	AGACATGTTGGTATTGCACA	73	0313-0332	AUG
31420	CAGACATGTTGGTATTGCAC	74	0314-0333	AUG
31558	CAGTAGGTACAGACATGTTG	75	0323-0342	coding
31723	TACAGCACCATCAGTAGGTA	76	0334-0353	coding
31421	GGAATCTGTGAGGTGGTTAC	77	0351-0370	coding
31559	TTCCGAAGCTGGAATCTGTG	78	0361-0380	coding
31724	AGGGTCTCTTGTTCCGAAGC	79	0372-0391	coding
31422	GCTTTGGTCTAACCAGGGTC	80	0386-0405	coding
31560	GCAATGGCTTTGGTCTAACC	81	0392-0411	coding
31725	TAACTTCAAAAGCAATGGCT	82	0403-0422	coding
31423	GTGCACCAACAGACTTTAAT	83	0422-0441	coding
31561	ACCTCTTTCATAGTATAAGT	84	0450-0469	coding
31726	ATAATATACTGGCCAAGATA	85	0477-0496	coding
31424	TAATCGTTTAGTCATAATAT	86	0490-0509	coding
31727	ATCATATAATCGTTTAGTCA	87	0496-0515	coding
31562	GCTTCTCATCATATAATCGT	88	0503-0522	coding
31728	CAATATGTTGTTGCTTCTCA	89	0515-0534	coding
31425	GAACAATATACAATATGTTG	90	0525-0544	coding
31729	TCATTTGAACAATATACAAT	91	0531-0550	coding
31563	TAGAAGATCATTTGAACAAT	92	0538-0557	coding
31730	AACAAATCTCCTAGAAGATC	93	0549-0568	coding
31426	TGGCACGCCAAACAAATCTC	94	0559-0578	coding
31731	AGAAGCTTGGCACGCCAAAC	95	0566-0585	coding
31564	CTTTCACAGAGAAGCTTGGC	96	0575-0594	coding
31732	TTTTCCTGTGCTCTTTCACA	97	0587-0606	coding
31427	TATATATTTTCCTGTGCTCT	98	0593-0612	coding
31733	ATCATGGTATATATTTTCCT	99	0600-0619	coding
31565	TTCCTGTAGATCATGGTATA	100	0609-0628	coding
31734	TACTACCAAGTTCCTGTAGA	101	0619-0638	coding
31428	TTCCTGCTGATTGACTACTA	102	0634-0653	coding
31566	TGAGTCCGATGATTCCTGCT	103	0646-0665	coding
31735	CAGATGTACCTGAGTCCGAT	104	0656-0675	coding
31429	CTGTTCTCACTCACAGATGT	105	0669-0688	coding
31567	TTCAAGGTGACACCTGTTCT	106	0682-0701	coding
31736	ACTCCCACCTTCAAGGTGAC	107	0691-0710	coding
31430	GGTCCTTTTGATCACTCCCA	108	0704-0723	coding
31568	AAGCTCTTGTACAAGGTCCT	109	0718-0737	coding
31737	CTCTTCCTGAAGCTCTTGTA	110	0727-0746	coding
31431	AAGATGAAGGTTTCTCTTCC	111	0740-0759	coding
31569	AAACCAAATGTGAAGATCAA	112	0752-0771	coding
31738	ATGGTCTAGAAACCAAATGT	113	0761-0780	coding
31432	CTAGATGAGGTAGATGGTCT	114	0774-0793	coding
31570	AATTGCTCTCCTTCTAGATG	115	0787-0806	coding
31739	TCTGTCTCACTAATTGCTCT	116	0798-0817	coding
31433	TCTGAATTTTCTTCTGTCTC	117	0810-0829	coding
31571	CACCAGATAATTCATCTCAA	118	0824-0843	coding
31740	TTTGTCGTTCACCAGATAAT	119	0833-0852	coding
31434	GTGGCGTTTTCTTTGTCGTT	120	0844-0863	coding
31572	TACTATCAGATTTGTGGCGT	121	0857-0876	coding
31741	GAAAGGCAAATACTATCACA	122	0867-0886	coding
31435	GCTTTCATCAAAGGAAAGGG	123	0880-0899	coding
31573	TACACACAGAGCCAGGCTTT	124	0895-0914	coding
31742	CTCCCTTATTACACACAGAG	125	0904-0923	coding
31436	TCACAACATATCTCCCTTAT	126	0915-0934	coding
31574	CTACTGCTTCTTTCACAACA	127	0927-0946	coding
31743	GATTCACTGCTACTGCTTCT	128	0936-0955	coding
31437	TGGCGTCCCTGTAGATTCAC	129	0949-0968	coding
31575	AAGATCCGGATTCGATGGCG	130	0964-0983	coding
31744	CAGCATCAAGATCCGGATTC	131	0971-0990	coding
31438	GTTCACTTACACCAGCATCA	132	0983-1002	coding
31576	CAATCACCTGAATGTTCACT	133	0996-1015	coding
31745	CTGATCCAACCAATCACCTG	134	1006-1025	coding
31439	GAAACTGAATCCTGATCCAA	135	1017-1036	coding
31746	TGATCTGAAACTGAATCCTG	136	1023-1042	coding
31577	CTACACTAAACTGATCTGAA	137	1034-1053	coding
31747	CAACTTCAAATTCTACACTA	138	1046-1065	coding
31440	AGATTCAACTTCAAATTCTA	139	1051-1070	coding
31748	GAGTCGAGAGATTCAACTTC	140	1059-1078	coding
31578	TAATCTTCTGAGTCGAGAGA	141	1068-1087	coding
31749	CTAAGGCTATAATCTTCTGA	142	1077-1096	coding
31441	TTCTTCACTAAGGCTATAAT	143	1084-1103	coding
31750	TCTTGTCCTTCTTCACTAAG	144	1092-1111	coding
31579	CTGAGAGTTCTTGTCCTTCT	145	1100-1119	coding
31751	TTCATCTGAGAGTTCTTGTC	146	1105-1124	coding
31442	CCTCATCATCTTCATCTGAG	147	1115-1134	coding
31752	CTTGATATACCTCATCATCT	148	1124-1143	coding
31753	ATACACAGTAA(TTGATATA	149	1135-1154	coding
31443	CTCTCCCCTGCCTGATACAC	150	1149-1168	coding
31580	GAATCTGTATCACTCTCCCC	151	1161-1180	coding
31754	TCTTCAAATGAATCTGTATC	152	1170-1189	coding
31444	AAATTTCAGGATCTTCTTCA	153	1184-1203	coding
31581	AGTCAGCTAAGGAAATTTCA	154	1196-1215	coding
31755	GCATTTCCAATAGTCAGCTA	155	1207-1226	coding
31445	CATTGCATGAAGTGCATTTC	156	1220-1239	coding
31756	TCATTTCATTGCATGAAGTG	157	1226-1245	coding
31582	CATCTGTTGCAATGTGATGG	158	1257-1276	coding
31757	GAAGGGCCCAACATCTGTTG	159	1268-1287	coding
31446	TTCTCACGAAGGGCCCAACA	160	1275-1294	coding
31758	GAAGCCAATTCTCACGAAGG	161	1283-1302	coding
31583	TATCTTCAGGAAGCCAATTC	162	1292-1311	coding
31759	CTTTCCCTTTATCTTCAGGA	163	1301-1320	coding
31447	TCCCCTTTATCTTTCCCTTT	164	1311-1330	coding
31584	CTTTCTCAGAGATTTCCCCT	165	1325-1344	coding
31760	CAGTTTGGCTTTCTCAGAGA	166	1333-1352	coding
31448	GTGTTGAGTTTTCCAGTTTG	167	1346-1365	coding
31585	CCTCTTCAGCTTGTGTTGAG	168	1358-1377	coding
31761	ACATCAAAGCCCTCTTCAGC	169	1368-1787	coding
31449	GAATCATTCACTATAGTTTT	170	1401-1420	coding
31586	ATGACTCTCTGGAATCATTC	171	1412-1431	coding
31762	CCTCAACACATGACTCTCTG	172	1421-1440	coding
31450	TTATCATCATTTTCCTCAAC	173	1434-1453	coding
31763	TAATTTTATCATCATTTTCC	174	1439-1458	coding
31587	GAAGCTTGTGTAATTTTATC	175	1449-1468	coding
31764	TGATTGTGAAGCTTGTGTAA	176	1456-1475	coding
31451	CACTTTCTTGTGATTGTGAA	177	1466-1485	coding
31588	GCTGAGAATAGTCTTCACTT	178	1481-1500	coding
31765	AGTTGATGGCTGAGAATAGT	179	1489-1508	coding
31452	TGCTACTAGAAGTTGATGGC	180	1499-1518	coding
31766	TAAATAATGCTACTAGAAGT	181	1506-1525	coding
31589	CTTGGCTGCTATAAATAATG	182	1517-1536	coding
31590	ATCTTCTTGGCTGCTATAAA	183	1522-1541	coding
31453	AACTCTTTCACATCTTCTTG	184	1533-1552	coding
31767	CCCTTTCAAACTCTTTCACA	185	1541-1560	coding
31591	GGGTTTCTTCCCTTTCAAAC	186	1550-1569	coding
31768	TCTTTGTCTTGGGTTTCTTC	187	1560-1579	coding
31454	CTCTCTTCTTTGTCTTGGGT	188	1566-1585	coding
31592	AACTAGATTCCACACTCTCT	189	1580-1599	coding
31769	CAAGGTTCAATGGCATTAAG	190	1605-1624	coding
31455	TGACAAATCACACAAGGTTC	191	1617-1636	coding
31593	TCGACCTTGACAAATCACAC	192	1624-1643	coding
31594	ATGGACAATGCAACCATTTT	193	1648-1667	coding
31770	TGTTTTGCCATGGACAATGC	194	1657-1676	coding
31456	TAAGATGTCCTGTTTTGCCA	195	1667-1686	coding
31595	GCAGGCCATAAGATGTCCTG	196	1675-1694	coding
31596	ACATGTAAAGCAGGCCATAA	197	1684-1703	coding
31771	CTTTGCACATGTAAAGCAGG	198	1690-1709	coding
31457	TTTCTTTAGCTTCTTTGCAC	199	1702-1721	coding
31597	TTATTCCTTTTCTTTAGCTT	200	1710-1729	coding
31598	TGGGCAGGGCTTATTCCTTT	201	1720-1739	coding
31772	ACATACTGGGCAGGGCTTAT	202	1726-1745	coding
31458	TTGGTTGTCTACATACTGGG	203	1736-1755	coding
31599	TCATTTGAATTGGTTGTCTA	204	1745-1764	coding
31600	AAGTTAGCACAATCATTTGA	205	1757-1776	coding
31601	TCTCTTATAGACAGGTCAAC	206	1787-1806	STOP
31459	AAATATATAATTCTCTTATA	207	1798-1817	3′ UTR
31602	AGTTAGAAATATATAATTCT	208	1804-1823	3′ UTR
31773	ATATAGTTAGAAATATATAA	209	1808-1827	3′ UTR
31603	CTAGGGTTATATAGTTAGAA	210	1816-1835	3′ UTR
31774	TAAATTCCTAGGGTTATATA	211	1823-1842	3′ UTR
31460	CAGGTTGTCTAAATTCCTAG	212	1832-1851	3′ UTR
31604	ATAAATTTCAGGTTGTCTAA	213	1840-1859	3′ UTR
31605	ATATATGTGAATAAATTTCA	214	1850-1869	3′ UTR
31606	CTTTGATATATGTGAATAAA	215	1855-1874	3′ UTR
31461	CATTTTCTCACTTTGATATA	216	1865-1884	3′ UTR
31607	ATTGAGGCATTTTCTCACTT	217	1872-1891	3′ UTR
31608	AATCTATGTGAATTGAGGCA	218	1883-1902	3′ UTR
31609	AGAAGAAATCTATGTGAATT	219	1889-1908	3′ UTR
31462	ATACTAAAGAGAAGAAATCT	220	1898-1917	3′ UTR
31610	GTCAATTATACTAAAGAGAA	221	1905-1924	3′ UTR
31775	TAGGTCAATTATACTAAAGA	222	1908-1927	3′ UTR
31611	CAAAGTAGGTCAATTATACT	223	1913-1932	3′ UTR
31776	CCACTACCAAAGTAGGTCAA	224	1920-1939	3′ UTR
31463	AGTATTCACTATTCCACTAC	225	1933-1952	3′ UTR
31612	TATAGTAAGTATTCACTATT	226	1940-1959	3′ UTR
31613	AGTCAAATTATAGTAAGTAT	227	1948-1967	3′ UTR
31777	CATATTCAAGTCAAATTATA	228	1956-1975	3′ UTR
31464	AAAGGATGAGCTACATATTC	229	1969-1988	3′ UTR
31778	GTGTAAAGGATGAGCTACAT	230	1973-1992	3′ UTR
31614	TAGGAGTTGGTGTAAAGGAT	231	1982-2001	3′ UTR
31779	TTTAAAATTAGGAGTTGGTG	232	1990-2009	3′ UTR
31615	GAAATTATTTAAAATTAGGA	233	1997-2016	3′ UTR
31465	CAGAGTAGAAATTATTTAAA	234	2004-2023	3′ UTR
31616	CTCATTTAAGACAGAGTAGA	235	2015-2034	3′ UTR
31780	TACTTCTCATTTAAGACAGA	236	2020-2039	3′ UTR
31617	CATATACATATTTAAGAAAA	237	2051-2070	3′ UTR
31466	TTAAATGTCATATACATATT	238	2059-2078	3′ UTR
31618	TAATAAGTTACATTTAAATG	239	2072-2091	3′ UTR
31619	GTAACAGAGCAAGACTCGGT	240	2103-2122	3′ UTR
31467	CAGCCTGGGTAACAGAGCAA	241	2111-2130	3′ UTR
31781	CACTCCAGCCTGGGTAACAG	242	2116-2135	3′ UTR
31620	CCCACTGCACTCCAGCCTGG	243	2123-2142	3′ UTR
31782	GCCAAGATCACCCACTGCAC	244	2133-2152	3′ UTR
31621	GCAGTGAGCCAAGATCACCC	245	2140-2159	3′ UTR
31468	GAGCTTGCAGTGAGCCAAGA	246	2146-2165	3′ UTR
31783	GAGGGCAGAGCTTGCAGTGA	247	2153-2172	3′ UTR
31622	CAGGAGAATGGTGCGAACCC	248	2176-2195	3′ UTR
31623	AGGCTGAGGCAGGAGAATGG	249	2185-2204	3′ UTR
31784	ATTGGGAGGCTGAGGCAGGA	250	2191-2210	3′ UTR
31469	CAAGCTAATTGGGAGGCTGA	251	2198-2217	3′ UTR
31624	AGGCCAAGCTAATTGGGAGG	252	2202-2221	3′ UTR
31785	ATGACTGTAGGCCAAGCTAA	253	2210-2229	3′ UTR
31625	CAGATGACTGTAGGCCAAGC	254	2213-2232	3′ UTR
31786	GGTGGCAGATGACTGTAGGC	255	2218-2237	3′ UTR
31626	AGGTGTGGTGGCAGATGACT	21	2224-2243	3′ UTR
31470	AATTAGCCAGGTGTGGTGGC	256	2232-2251	3′ UTR
31627	GTCTCTACTAAAAGTACAAA	257	2253-2272	3′ UTR
31628	CGGTGAAACCCTGTCTCTAC	258	2265-2284	3′ UTR
31787	TGGCTAACACGGTGAAACCC	259	2274-2293	3′ UTR
31471	AGACCATCCTGGCTAACACG	260	2283-2302	3′ UTR
31788	GAGATCGAGACCATCCTGGC	261	2290-2309	3′ UTR
31629	GAGGTCAGGAGATCGAGACC	262	2298-2317	3′ UTR
31789	GCGGATCACGAGGTCAGGAG	263	2307-2326	3′ UTR
31472	AGGCCGAGGTGGGCGGATCA	264	2319-2338	3′ UTR
31790	TTTGGGAGGCCGAGGTGGGC	265	2325-2344	3′ UTR
31630	TCCCAGCACTTTGGGAGGCC	266	2334-2353	3′ UTR
31791	CCTGTAATCCCAGCACTTTG	267	2341-2360	3′ UTR
31631	GTGGCTCATGCCTGTAATCC	268	2351-2370	3′ UTR

TABLE 11


Nucleotide Sequences of Human mdm2
Chimeric (deoxy gapped) Oligonucleotides

		SEQ	TARGET GENE	GENE
ISIS	NUCLEOTIDE SEQUENCE¹	ID	NUCLEOTIDE	TARGET
NO.	(5′ ->3′)	NO:	CO-ORDINATES²	REGION

31393	CAGCCAAGCTCGCGCGGTGC	3	0001-0020	5' UTR
31712	AAGCAGCCAAGCTCGCGCGG	33	0004-0023	5' UTR
31552	CAGGCCCCAGAAGCAGCCAA	34	0014-0033	5' UTR
31713	GCCACACAGGCCCCAGAAGC	35	0020-0039	5' UTR
31394	ACACACAGGGCCACACAGGC	36	0029-0048	5' UTR
31714	TTCCGACACACAGGGCCACA	37	0034-0053	5' UTR
31553	GCTCCATCTTTCCGACACAC	38	0043-0062	5' UTR
31715	GCTTCTTGCTCCATCTTTCC	39	0050-0069	5' UTR
31395	CCCTCGGGCTCGGCTTCTTG	40	0062-0081	5' UTR
31716	GCGGCCGCCCCTCGGGCTCG	41	0070-0089	5' UTR
31554	AAGCAGCAGGATCTCGGTCA	42	0098-0107	5' UTR
31717	GCTGCGAAAGCAGCAGGATC	43	0105-0124	5' UTR
31396	TGCTCCTGGCTGCGAAAGCA	44	0113-0132	5' UTR
31718	GGGACGGTGCTCCTGGCTGC	45	0120-0139	5' UTR
31555	ACTGGGCGCTCGTACGCACT	46	0150-0169	5' UTR
31719	GCCAGGGCACTGGGCGCTCG	47	0158-0177	5' UTR
31397	TCTCCGGGCCAGGGCACTGG	48	0165-0184	5' UTR
31720	TCATTCCACTCTCCGGGCCA	49	0174-0193	5' UTR
31556	GGAAGCACGACGCCCTGGGC	50	0202-0221	5' UTR
31721	TACTGCGGAAGCACGACGCC	51	0208-0227	5' UTR
31398	GGGACTGACTACTGCGGAAG	52	0217-0236	5' UTR
31722	TCAAGACTCCCCAGTTTCCT	53	0242-0261	5' UTR
31557	CCTGCTCCTCACCATCCGGG	54	0289-0308	5' UTR
31399	TTTGCCTGCTCCTCACCATC	55	0293-0312	AUG
31400	ATTTGCCTGCTCCTCACCAT	56	0294-0313	AUG
31401	CATTTGCCTGCTCCTCACCA	9	0295-0314	AUG
31402	ACATTTGCCTGCTCCTCACC	57	0296-0315	AUG
31403	CACATTTGCCTGCTCCTCAC	58	0297-0316	AUG
31404	GCACATTTGCCTGCTCCTCA	59	0298-0317	AUG
31405	TGCACATTTGCCTGCTCCTC	60	0299-0318	AUG
31406	TTGCACATTTGCCTGCTCCT	61	0300-0319	AUG
31407	ATTGCACATTTGCCTGCTCC	62	0301-0320	AUG
31408	TATTGCACATTTGCCTGCTC	63	0302-0321	AUG
31409	GTATTGCACATTTCCCTGCT	10	0303-0322	AUG
31410	GGTATTGCACATTTGCCTGC	64	0304-0323	AUG
31411	TGGTATTGCACATTTGCCTG	65	0305-0324	AUG
31412	TTGGTATTGCACATTTGCCT	66	0306-0325	AUG
31413	GTTGGTATTGCACATTTGCC	67	0307-0326	AUG
31414	TGTTGGTATTGCACATTTGC	68	0308-0327	AUG
31415	ATGTTGGTATTGCACATTTG	69	0309-0328	AUG
31416	CATGTTGGTATTGCACATTT	70	0310-0329	AUG
31417	ACATGTTGGTATTGCACATT	71	0311-0330	AUG
31418	GACATGTTGGTATTGCACAT	72	0312-0331	AUG
31419	AGACATGTTGGTATTGCACA	73	0313-0332	AUG
31420	CAGACATGTTGGTATTGCAC	74	0314-0333	AUG
31558	CAGTAGGTACAGACATGTTG	75	0323-0342	coding
31723	TACAGCACCATCAGTAGGTA	76	0334-0353	coding
31421	GGAATCTGTGAGGTGGTTAC	77	0351-0370	coding
31559	TTCCGAAGCTGGAATCTGTG	78	0361-0380	coding
31724	AGGGTCTCTTGTTCCGAAGC	79	0372-0391	coding
31422	GCTTTGGTCTAACCAGGGTC	80	0386-0405	coding
31560	GCAATGGCTTTGGTCTAACC	81	0392-0411	coding
31725	TAACTTCAAAAGCAATGGCT	82	0403-0422	coding
31423	GTGCACCAACAGACTTTAAT	83	0422-0441	coding
31561	ACCTCTTTCATAGTATAAGT	84	0450-0469	coding
31726	ATAATATACTGGCCAAGATA	85	0477-0496	coding
31424	TAATCGTTTAGTCATAATAT	86	0490-0509	coding
31727	ATCATATAATCGTTTAGTCA	87	0496-0515	coding
31562	GCTTCTCATCATATAATCGT	88	0503-0522	coding
31728	CAATATGTTGTTGCTTCTCA	89	0515-0534	coding
31425	GAACAATATACAATATGTTG	90	0525-0544	coding
31729	TCATTTGAACAATATACAAT	91	0531-0550	coding
31563	TAGAAGATCATTTGAACAAT	92	0538-0557	coding
31730	AACAAATCTCCTAGAAGATC	93	0549-0568	coding
31426	TGGCACGCCAAACAAATCTC	94	0559-0578	coding
31731	AGAAGCTTGGCACGCCAAAC	95	0566-0585	coding
31564	CTTTCACAGAGAAGCTTGGC	96	0575-0594	coding
31732	TTTTCCTGTGCTCTTTCACA	97	0587-0606	coding
31427	TATATATTTTCCTGTGCTCT	98	0593-0612	coding
31733	ATCATGGTATATATTTTCCT	99	0600-0619	coding
31565	TTCCTGTAGATCATGGTATA	100	0609-0628	coding
31734	TACTACCAAGTTCCTGTAGA	101	0619-0638	coding
31428	TTCCTGCTGATTGACTACTA	102	0634-0653	coding
31566	TGAGTCCGATGATTCCTGCT	103	0646-0665	coding
31735	CAGATGTACCTGAGTCCGAT	104	0656-0675	coding
31429	CTGTTCTCACTCACAGATGT	105	0669-0688	coding
31567	TTCAAGGTGACACCTGTTCT	106	0682-0701	coding
31736	ACTCCCACCTTCAAGGTGAC	107	0691-0710	coding
31430	GGTCCTTTTGATCACTCCCA	108	0704-0723	coding
31568	AAGCTCTTGTACAAGGTCCT	109	0718-0737	coding
31737	CTCTTCCTGAAGCTCTTGTA	110	0727-0746	coding
31431	AAGATGAAGGTTTCTCTTCC	111	0740-0759	coding
31569	AAACCAAATGTGAAGATGAA	112	0752-0771	coding
31738	ATGGTCTAGAAACCAAATGT	113	0761-0780	coding
31432	CTAGATGAGGTAGATGGTCT	114	0774-0793	coding
31570	AATTGCTCTCCTTCTAGATG	115	0787-0806	coding
31739	TCTGTCTCACTAATTGCTCT	116	0798-0817	coding
31433	TCTGAATTTTCTTCTGTCTC	117	0810-0829	coding
31571	CACCAGATAATTCATCTGAA	118	0824-0843	coding
31740	TTTGTCGTTCACCAGATAAT	119	0833-0852	coding
31434	GTGGCGTTTTCTTTGTCGTT	120	0844-0863	coding
31572	TACTATCAGATTTGTGGCGT	121	0857-0876	coding
31741	GAAAGGGAAATACTATCAGA	122	0867-0886	coding
31435	GCTTTCATCAAAGGAAAGGG	123	0880-0899	coding
31573	TACACACAGAGCCAGGCTTT	124	0895-0914	coding
31742	CTCCCTTATTACACACAGAG	125	0904-0923	coding
31436	TCACAACATATCTCCCTTAT	126	0915-0934	coding
31574	CTACTGCTTCTTTCACAACA	127	0927-0946	coding
31743	GATTCACTGCTACTGCTTCT	128	0936-0955	coding
31437	TGGCGTCCCTGTAGATTCAC	129	0949-0968	coding
31575	AAGATCCGGATTCGATGGCG	130	0964-0983	coding
31744	CAGCATCAAGATCCGGATTC	131	0971-0990	coding
31438	GTTCACTTACACCAGCATCA	132	0983-1002	coding
31576	CAATCACCTGAATGTTCACT	133	0996-1015	coding
31745	CTGATCCAACCAATCACCTG	134	1006-1025	coding
31439	GAAACTGAATCCTGATCCAA	135	1017-1036	coding
31746	TGATCTGAAACTGAATCCTG	136	1023-1042	coding
31577	CTACACTAAACTGATCTGAA	137	1034-1053	coding
31747	CAACTTCAAATTCTACACTA	138	1046-1065	coding
31440	AGATTCAACTTCAAATTCTA	139	1051-1070	coding
31748	GAGTCGAGAGATTCAACTTC	140	1059-1078	coding
31578	TAATCTTCTGAGTCGAGAGA	141	1068-1087	coding
31749	CTAAGGCTATAATCTTCTGA	142	1077-1096	coding
31441	TTCTTCACTAAGGCTATAAT	143	1084-1103	coding
31750	TCTTGTCCTTCTTCACTAAG	144	1092-1111	coding
31579	CTGAGAGTTCTTGTCCTTCT	145	1100-1119	coding
31751	TTCATCTGAGAGTTCTTGTC	146	1105-1124	coding
31442	CCTCATCATCTTCATCTGAG	147	1115-1134	coding
31752	CTTGATATACCTCATCATCT	148	1124-1143	coding
31753	ATACACAGTAACTTGATATA	149	1135-1154	coding
31443	CTCTCCCCTGCCTGATACAC	150	1149-1168	coding
31580	GAATCTGTATCACTCTCCCC	151	1161-1180	coding
31754	TCTTCAAATGAATCTGTATC	152	1170-1189	coding
31444	AAATTTCAGGATCTTCTTCA	153	1184-1203	coding
31581	AGTCAGCTAAGGAAATTTCA	154	1196-1215	coding
31755	GCATTTCCAATAGTCAGCTA	155	1207-1226	coding
31445	CATTGCATGAAGTGCATTTC	156	1220-1239	coding
31756	TCATTTCATTGCATGAAGTG	157	1226-1245	coding
31582	CATCTGTTGCAATGTGATGG	158	1257-1276	coding
31757	GAAGGGCCCAACATCTGTTG	159	1268-1287	coding
31446	TTCTCACGAAGGGCCCAACA	160	1275-1294	coding
31758	GAAGCCAATTCTCACGAACG	161	1283-1302	coding
31583	TATCTTCAGGAAGCCAATTC	162	1292-1311	coding
31759	CTTTCCCTTTATCTTCAGGA	163	1301-1320	coding
31447	TCCCCTTTATCTTTCCCTTT	164	1311-1330	coding
31584	CTTTCTCAGAGATTTCCCCT	165	1325-1344	coding
31760	CAGTTTGGCTTTCTCAGAGA	166	1333-1352	coding
31448	GTGTTGAGTTTTCCAGTTTG	167	1346-1365	coding
31585	CCTCTTCAGCTTGTGTTGAG	168	1358-1377	coding
31761	ACATCAAAGCCCTCTTCAGC	169	1368-1787	coding
31449	GAATCATTCACTATAGTTTT	170	1401-1420	coding
31586	ATGACTCTCTGGAATCATTC	171	1412-1431	coding
31762	CCTCAACACATGACTCTCTG	172	1421-1440	coding
31450	TTATCATCATTTTCCTCAAC	173	1434-1453	coding
31763	TAATTTTATCATCATTTTCC	174	1439-1458	coding
31587	GAAGCTTGTGTAATTTTATC	175	1449-1468	coding
31764	TGATTGTGAAGCTTGTGTAA	176	1456-1475	coding
31451	CACTTTCTTGTGATTGTGAA	177	1466-1485	coding
31588	GCTGAGAATAGTCTTCACTT	178	1481-1500	coding
31765	AGTTGATGGCTGAGAATAGT	179	1489-1508	coding
31452	TGCTACTAGAAGTTGATGGC	180	1499-1518	coding
31766	TAAATAATGCTACTAGAAGT	181	1506-1525	coding
31589	CTTGGCTGCTATAAATAATG	182	1517-1536	coding
31590	ATCTTCTTGGCTGCTATAAA	183	1522-1541	coding
31453	AACTCTTTCACATCTTCTTG	184	1533-1552	coding
31767	CCCTTTCAAACTCTTTCACA	185	1541-1560	coding
31591	GGGTTTCTTCCCTTTCAAAC	186	1550-1569	coding
31768	TCTTTGTCTTGGGTTTCTTC	187	1560-1579	coding
31454	CTCTCTTCTTTGTCTTGGGT	188	1566-1585	coding
31592	AACTAGATTCCACACTCTCT	189	1580-1599	coding
31769	CAAGGTTCAATGGCATTAAG	190	1605-1624	coding
31455	TGACAAATCACACAAGGTTC	191	1617-1636	coding
31593	TCGACCTTGACAZATCACAC	192	1624-1643	coding
31594	ATGGACAATGCAACCATTTT	193	1648-1667	coding
31770	TGTTTTGCCATGGACAATGC	194	1657-1676	coding
31456	TAAGATGTCCTGTTTTGCCA	195	1667-1686	coding
31595	GCAGGCCATAAGATGTCCTG	196	1675-1694	coding
31596	ACATGTAAAGCAGGCCATAA	197	1684-1703	coding
31771	CTTTGCACATGTAAAGCAGG	198	1690-1709	coding
31457	TTTCTTTAGCTTCTTTGCAC	199	1702-1721	coding
31597	TTATTCCTTTTCTTTAGCTT	200	1710-1729	coding
31598	TGGGCAGGGCTTATTCCTTT	201	1720-1739	coding
31772	ACATACTGGGCAGGGCTTAT	202	1726-1745	coding
31458	TTGGTTGTCTACATACTGGG	203	1736-1755	coding
31599	TCATTTGAATTGGTTGTCTA	204	1745-1764	coding
31600	AAGTTAGCACAATCATTTGA	205	1757-1776	coding
31601	TCTCTTATAGACAGGTCAAC	206	1787-1806	STOP
31459	AAATATATAATTCTCTTATA	207	1798-1817	3' UTR
31602	AGTTAGAAATATATAATTCT	208	1804-1823	3' UTR
31773	ATATAGTTAGAAATATATAA	209	1808-1827	3' UTR
31603	CTAGGGTTATATAGTTAGAA	210	1816-1835	3' UTR
31774	TAAATTCCTAGGGTTATATA	211	1823-1842	3' UTR
31460	CAGGTTGTCTJAATTCCTAG	212	1832-1851	3' UTR
31604	ATAAATTTCAGGTTGTCTAA	213	1840-1859	3' UTR
31605	ATATATGTGAATAAATTTCA	214	1850-1869	3' UTR
31606	CTTTGATATATGTGAATAAA	215	1855-1874	3' UTR
31461	CATTTTCTCACTTTGATATA	216	1865-1884	3' UTR
31607	ATTGAGGCATTTTCTCACTT	217	1872-1891	3' UTR
31608	AATCTATGTGAATTGAGGCA	218	1883-1902	3' UTR
31609	AGAAGAAATCTATGTGAATT	219	1889-1908	3' UTR
31462	ATACTAAAGAGAAGAAATCT	220	1898-1917	3' UTR
31610	GTCAATTATACTAAAGAGAA	221	1905-1924	3' UTR
31775	TAGGTCAATTATACTAAAGA	222	1908-1927	3' UTR
31611	CAAAGTAGGTCAATTATACT	223	1913-1932	3' UTR
31776	CCACTACCAAAGTAGGTCAA	224	1920-1939	3' UTR
31463	AGTATTCACTATTCCACTAC	225	1933-1952	3' UTR
31612	TATAGTAAGTATTCACTATT	226	1940-1959	3' UTR
31613	AGTCAAATTATAGTAAGTAT	227	1948-1967	3' UTR
31777	CATATTCAAGTCAAATTATA	228	1956-1975	3' UTR
31464	AAAGGATGAGCTACATATTC	229	1969-1988	3' UTR
31778	GTGTAAAGGATGAGCTACAT	230	1973-1992	3' UTR
31614	TAGGAGTTGGTGTAAAGGAT	231	1982-2001	3' UTR
31779	TTTAAAATTAGGAGTTGGTG	232	1990-2009	3' UTR
31615	GAAATTATTTAAAATTAGGA	233	1997-2016	3' UTR
31465	CAGAGTAGAAATTATTTAAA	234	2004-2023	3' UTR
31616	CTCATTTAAGACAGAGTAGA	235	2015-2034	3' UTR
31780	TACTTCTCATTTAXGACAGA	236	2020-2039	3' UTR
31617	CATATACATATTTAAGAAAA	237	2051-2070	3' UTR
31466	TTAAATGTCATATACATATT	238	2059-2078	3' UTR
31618	TAATAAGTTACATTTAAATG	239	2072-2091	3' UTR
31619	GTAACAGAGCAAGACTCGGT	240	2103-2122	3' UTR
31467	CAGCCTGGGTPICAGAGCAA	241	2111-2130	3' UTR
31781	CACTCCAGCCTGGGTAACAG	242	2116-2135	3' UTR
31620	CCCACTGCACTCCAGCCTGG	243	2123-2142	3' UTR
31782	GCCAAGATCACCCACTGCAC	244	2133-2152	3' UTR
31621	GCAGTGAGCCAAGATCACCC	245	2140-2159	3' UTR
31468	GAGCTTGCAGTGAGCCAACA	246	2146-2165	3' UTR
31783	GAGGGCAGAGCTTGCAGTGA	247	2153-2172	3' UTR
31622	CAGGAGAATGGTGCGAACCC	248	2176-2195	3' UTR
31623	AGGCTGAGGCAGGAGAATGG	249	2185-2204	3' UTR
31784	ATTGGGAGGCTGAGGCAGGA	250	2191-2210	3' UTR
31469	CAAGCTAATTGGGAGGCTGA	251	2198-2217	3' UTR
31624	AGGCCAAGCTAATTGGGAGG	252	2202-2221	3' UTR
31785	ATGACTGTAGGCCAAGCTAA	253	2210-2229	3' UTR
31625	CAGATGACTGTAGGCCAAGC	254	2213-2232	3' UTR
31786	GGTGGCAGATGACTGTAGGC	255	2218-2237	3' UTR
31626	AGGTGTGGTGGCAGATGACT	21	2224-2243	3' UTR
31470	AATTAGCCAGGTGTGGTGGC	256	2232-2251	3' UTR
31627	GTCTCTACTAAAAGTACAAA	257	2253-2272	3' UTR
31628	CGGTGAAACCCTGTCTCTAC	258	2265-2284	3' UTR
31787	TGGCTAACACGGTGAAACCC	259	2274-2293	3' UTR
31471	AGACCATCCTGGCTAACACG	260	2283-2302	3' UTR
31788	GAGATCGAGACCATCCTGGC	261	2290-2309	3' UTR
31629	GAGGTCAGGAGATCGAGACC	262	2298-2317	3' UTR
31789	GCGGATCACGAGGTCAGGAG	263	2307-2326	3' UTR
31472	AGGCCGAGGTGGGCGGATCA	264	2319-2338	3' UTR
31790	TTTGGGAGGCCGAGGTGGGC	265	2325-2344	3' UTR
31630	TCCCAGCACTTTGGGAGGCC	266	2334-2353	3' UTR
31791	CCTGTAATCCCAGCACTTTG	267	2341-2360	3' UTR
31631	GTGGCTCATGCCTGTAATCC	268	2351-2370	3' UTR

Oligonucleotide activity was assayed by quantitation of mdm2 mRNA levels by real-time PCR (RT-PCR) using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in RT-PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. The primers and probes used were: Forward: 5′-GGCAAATGTGCAATACCAACA-3′ (SEQ ID NO. 269) Reverse: 5′-TGCACCAACAGACTTTAATAACTTCA-3′(SEQ ID NO. 270) Probe: 5′-FAM-CCACCTCACAGATTCCAGCTTCGGA-TAMRA-3′ (SEQ ID NO. 271) [0105]
A reporter dye (e.g., JOE or FAM, PE-Applied Biosystems, Foster City, Calif.) was attached to the 5′ end of the probe and a quencher dye (e.g., TAMRA, PE-Applied Biosystems, Foster City, Calif.) was attached to the 3′ end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3′ quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5′-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular (six-second) intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples. [0106]
RT-PCR reagents were obtained from PE-Applied Biosystems, Foster City, Calif. RT-PCR reactions were carried out by adding 25 μl PCR cocktail (1x TAQMAN® buffer A, 5.5 mM MgCl[0107] ₂, 300 μM each of dATP, dCTP and dGTP, 600 μM of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 U RNAse inhibitor, 1.25 units AMPLITAQ GOLD®, and 12.5 U MuLV reverse transcriptase) to 96 well plates containing 25 μl poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48° C. Following a 10 minute incubation at 95° C. to activate the AMPLITAQ GOLD®, 40 cycles of a two-step PCR protocol were carried out: 95° C. for 15 seconds (denaturation) followed by 60° C. for 1.5 minutes (annealing/extension).

Results are shown in Table 12. Oligonucleotides 31394 (SEQ ID NO: 36), 31398 (SEQ ID NO: 52), 31400 (SEQ ID NO: 56), 31402 (SEQ ID NO: 57), 31405 (SEQ ID NO: 60), 31406 (SEQ ID NO: 61), 31415 (SEQ ID NO: 69) , 31416 (SEQ ID NO: 70), 31418 (SEQ ID NO: 72) , 31434 (SEQ ID NO: 60), 31436 (SEQ ID NO: 126), 31446 (SEQ ID NO: 160) , 31451 (SEQ ID NO: 177) , 31452 (SEQ ID NO: 180), 31456 (SEQ ID NO: 195) , 31461 (SEQ ID NO: 216) , 31468 (SEQ ID NO: 246) , 31469 (SEQ ID NO: 251) , 31471 (SEQ ID NO: 260) , and 31472 (SEQ ID NO: 264) gave at least approximately 50% reduction of mdm2 mRNA levels.

TABLE 12


Activities of Phosphorothioate Oligodeoxynucleotides
Targeted to Human mdm2

	SEQ	GENE
ISIS	ID	TARGET	% mRNA	% mRNA
No:	NO:	REGION	EXPRESSION	INHIBITION

LIPOFECTIN^T	—	—	100%	0%
^Monly	—

31393	3	5' UTR	59%	41%
31394	36	5' UTR	27%	73%
31395	40	5' UTR	96%	4%
31396	44	5' UTR	99%	1%
31397	48	5' UTR	76%	24%
31398	52	5' UTR	51%	49%
31399	55	AUG	138%	—
31400	56	AUG	22%	78%
31401	9	AUG	69%	31%
31402	57	AUG	47%	53%
31403	58	AUG	77%	23%
31404	59	AUG	60%	40%
31405	60	AUG	35%	65%
31406	61	AUG	45%	55%
31407	62	AUG	65%	35%
31408	63	AUG	71%	29%
31409	10	AUG	849%	—
31410	64	AUG	79%	21%
31411	65	AUG	67%	33%
31412	66	AUG	99%	1%
31413	67	AUG	68%	32%
31414	68	AUG	64%	36%
31415	69	AUG	48%	52%
31416	70	AUG	36%	64%
31417	71	AUG	77%	23%
31418	72	AUG	53%	47%
31419	73	AUG	122%	—
31420	74	AUG	57%	43%
31421	77	coding	111%	—
31422	80	coding	85%	15%
31423	83	coding	126%	—
31424	86	coding	70%	30%
31425	90	coding	95%	5%
31426	94	coding	69%	31%
31427	98	coding	9465%	—
31428	102	coding	81%	19%
31429	105	coding	138%	—
31430	108	coding	114%	—
31431	111	coding	77%	23%
31432	114	coding	676%	—
31433	117	coding	145%	—
31434	120	coding	40%	60%
31435	123	coding	193%	—
31436	126	coding	49%	51%
31437	129	coding	146%	—
31438	132	coding	76%	24%
31439	135	coding	104%	—
31440	139	coding	95%	5%
31441	143	coding	324%	—
31442	147	coding	1840%	—
31443	150	coding	369%	—
31444	153	coding	193%	—
31445	156	coding	106%	—
31446	160	coding	29%	71%
31447	164	coding	82%	18%
31448	167	coding	117%	—
31449	170	coding	1769%	—
31450	173	coding	84%	16%
31451	177	coding	49%	51%
31452	180	coding	33%	67%
31453	184	coding	59%	41%
31454	188	coding	171%	—
31455	191	coding	61%	39%
31456	195	coding	42%	58%
31457	199	coding	70%	30%
31458	203	coding	60%	40%
31459	207	3' UTR	149%	—
31460	212	3' UTR	71%	29%
31461	216	3' UTR	52%	48%
31462	220	3' UTR	1113%	—
31463	225	3' UTR	78%	22%
31464	229	3' UTR	112%	—
31465	234	3' UTR	66%	34%
31466	238	3' UTR	212%	—
31467	241	3' UTR	77%	23%
31468	246	3' UTR	17%	83%
31469	251	3' UTR	36%	64%
31470	256	3' UTR	60%	40%
31471	260	3' UTR	43%	57%
31472	264	3' UTR	35%	65%

Example 10

Effect of mdm2 Antisense Oligonucleotides on the Growth of Human A549 Lung Tumor Cells in Nude Mice

200 μl of A549 cells (5×10[0109] ⁶cells) are implanted subcutaneously in the inner thigh of nude mice. mdm2 antisense oligonucleotides are administered twice weekly for four weeks, beginning one week following tumor cell inoculation. Oligonucleotides are formulated with cationic lipids (LIPOFECTIN™L) and given subcutaneously in the vicinity of the tumor. Oligonucleotide dosage was 5 mg/kg with 60 mg/kg cationic lipid. Tumor size is recorded weekly.
Activity of the oligonucleotides is measured by reduction in tumor size compared to controls. [0110]

Example 11

U-87 Human Glioblastoma Cell Culture and Subcutaneous Xenografts into Nude Mice

The U-87 human glioblastoma cell line is obtained from the ATCC (Manassas, Va.) and maintained in Iscove's DMEM medium supplemented with heat-inactivated 10% fetal calf serum (Yazaki, T., et al., [0111] Mol. Pharmacol., 1996, 50, 236-242). Nude mice are injected subcutaneously with 2× 10⁷cells. Mice are injected intraperitoneally with oligonucleotide at dosages of either 2 mg/kg or 20 mg/kg for 21 consecutive days beginning 7 days after xenografts were implanted. Tumor volumes are measured on days 14, 21, 24, 31 and 35. Activity is measure by a reduced tumor volume compared to saline or sense oligonucleotide controls.

Example 12

Intracerebral U-87 Glioblastoma Xenografts into Nude Mice

U-87 cells are implanted in the brains of nude mice (Yazaki, T., et al., [0112] Mol. Pharmacol., 1996, 50, 236-242). Mice are treated via continuous intraperitoneal administration of antisense oligonucleotide (20 mg/kg), control sense oligonucleotide (20 mg/kg) or saline beginning on day 7 after xenograft implantation. Activity of the oligonucleotide is measured by an increased survival time compared to controls.
1 271 2372 base pairs Nucleic Acid Single Unknown No not provided J.D. Kinzler,K.W. Meltzer,P.S. George,D.L. Vogelstein,B. Oliner Amplification of a gene encoding a p53-associated protein in human sarcomas Nature 358 6381 80-83 02-JUL-1992 1 GCACCGCGCG AGCTTGGCTG CTTCTGGGGC CTGTGTGGCC CTGTGTGTCG 50 GAAAGATGGA GCAAGAAGCC GAGCCCGAGG GGCGGCCGCG ACCCCTCTGA 100 CCGAGATCCT GCTGCTTTCG CAGCCAGGAG CACCGTCCCT CCCCGGATTA 150 GTGCGTACGA GCGCCCAGTG CCCTGGCCCG GAGAGTGGAA TGATCCCCGA 200 GGCCCAGGGC GTCGTGCTTC CGCAGTAGTC AGTCCCCGTG AAGGAAACTG 250 GGGAGTCTTG AGGGACCCCC GACTCCAAGC GCGAAAACCC CGGATGGTGA 300 GGAGCAGGCA AATGTGCAAT ACCAACATGT CTGTACCTAC TGATGGTGCT 350 GTAACCACCT CACAGATTCC AGCTTCGGAA CAAGAGACCC TGGTTAGACC 400 AAAGCCATTG CTTTTGAAGT TATTAAAGTC TGTTGGTGCA CAAAAAGACA 450 CTTATACTAT GAAAGAGGTT CTTTTTTATC TTGGCCAGTA TATTATGACT 500 AAACGATTAT ATGATGAGAA GCAACAACAT ATTGTATATT GTTCAAATGA 550 TCTTCTAGGA GATTTGTTTG GCGTGCCAAG CTTCTCTGTG AAAGAGCACA 600 GGAAAATATA TACCATGATC TACAGGAACT TGGTAGTAGT CAATCAGCAG 650 GAATCATCGG ACTCAGGTAC ATCTGTGAGT GAGAACAGGT GTCACCTTGA 700 AGGTGGGAGT GATCAAAAGG ACCTTGTACA AGAGCTTCAG GAAGAGAAAC 750 CTTCATCTTC ACATTTGGTT TCTAGACCAT CTACCTCATC TAGAAGGAGA 800 GCAATTAGTG AGACAGAAGA AAATTCAGAT GAATTATCTG GTGAACGACA 850 AAGAAAACGC CACAAATCTG ATAGTATTTC CCTTTCCTTT GATGAAAGCC 900 TGGCTCTGTG TGTAATAAGG GAGATATGTT GTGAAAGAAG CAGTAGCAGT 950 GAATCTACAG GGACGCCATC GAATCCGGAT CTTGATGCTG GTGTAAGTGA 1000 ACATTCAGGT GATTGGTTGG ATCAGGATTC AGTTTCAGAT CAGTTTAGTG 1050 TAGAATTTGA AGTTGAATCT CTCGACTCAG AAGATTATAG CCTTAGTGAA 1100 GAAGGACAAG AACTCTCAGA TGAAGATGAT GAGGTATATC AAGTTACTGT 1150 GTATCAGGCA GGGGAGAGTG ATACAGATTC ATTTGAAGAA GATCCTGAAA 1200 TTTCCTTAGC TGACTATTGG AAATGCACTT CATGCAATGA AATGAATCCC 1250 CCCCTTCCAT CACATTGCAA CAGATGTTGG GCCCTTCGTG AGAATTGGCT 1300 TCCTGAAGAT AAAGGGAAAG ATAAAGGGGA AATCTCTGAG AAAGCCAAAC 1350 TGGAAAACTC AACACAAGCT GAAGAGGGCT TTGATGTTCC TGATTGTAAA 1400 AAAACTATAG TGAATGATTC CAGAGAGTCA TGTGTTGAGG AAAATGATGA 1450 TAAAATTACA CAAGCTTCAC AATCACAAGA AAGTGAAGAC TATTCTCAGC 1500 CATCAACTTC TAGTAGCATT ATTTATAGCA GCCAAGAAGA TGTGAAAGAG 1550 TTTGAAAGGG AAGAAACCCA AGACAAAGAA GAGAGTGTGG AATCTAGTTT 1600 GCCCCTTAAT GCCATTGAAC CTTGTGTGAT TTGTCAAGGT CGACCTAAAA 1650 ATGGTTGCAT TGTCCATGGC AAAACAGGAC ATCTTATGGC CTGCTTTACA 1700 TGTGCAAAGA AGCTAAAGAA AAGGAATAAG CCCTGCCCAG TATGTAGACA 1750 ACCAATTCAA ATGATTGTGC TAACTTATTT CCCCTAGTTG ACCTGTCTAT 1800 AAGAGAATTA TATATTTCTA ACTATATAAC CCTAGGAATT TAGACAACCT 1850 GAAATTTATT CACATATATC AAAGTGAGAA AATGCCTCAA TTCACATAGA 1900 TTTCTTCTCT TTAGTATAAT TGACCTACTT TGGTAGTGGA ATAGTGAATA 1950 CTTACTATAA TTTGACTTGA ATATGTAGCT CATCCTTTAC ACCAACTCCT 2000 AATTTTAAAT AATTTCTACT CTGTCTTAAA TGAGAAGTAC TTGGTTTTTT 2050 TTTTCTTAAA TATGTATATG ACATTTAAAT GTAACTTATT ATTTTTTTTG 2100 AGACCGAGTC TTGCTCTGTT ACCCAGGCTG GAGTGCAGTG GGTGATCTTG 2150 GCTCACTGCA AGCTCTGCCC TCCCCGGGTT CGCACCATTC TCCTGCCTCA 2200 GCCTCCCAAT TAGCTTGGCC TACAGTCATC TGCCACCACA CCTGGCTAAT 2250 TTTTTGTACT TTTAGTAGAG ACAGGGTTTC ACCGTGTTAG CCAGGATGGT 2300 CTCGATCTCC TGACCTCGTG ATCCGCCCAC CTCGGCCTCC CAAAGTGCTG 2350 GGATTACAGG CATGAGCCAC CG 2372 500 base pairs Nucleic Acid Single Unknown No not provided A. Flusberg, D. Haupt, Y. Barak, Y. Oren, M. Zauberman A functional p53-responsive intronic promoter is contained within the human mdm2 gene Nucleic Acids Res. 23 14 2584-2592 25-JUL-1995 2 GCTGCGGGC CCCTGCGGCG CGGGAGGTCC GGATGATCGC AGGTGCCTGT 50 CGGGTCACTA GTGTGAACGC TGCGCGTAGT CTGGGCGGGA TTGGGCCGGT 100 TCAGTGGGCA GGTTGACTCA GCTTTTCCTC TTGAGCTGGT CAAGTTCAGA 150 CACGTTCCGA AACTGCAGTA AAAGGAGTTA AGTCCTGACT TGTCTCCAGC 200 TGGGGCTATT TAAACCATGC ATTTTCCCAG CTGTGTTCAG TGGCGATTGG 250 AGGGTAGACC TGTGGGCACG GACGCACGCC ACTTTTTCTC TGCTGATCCA 300 GGTAAGCACC GACTTGCTTG TAGCTTTAGT TTTAACTGTT GTTTATGTTC 350 TTTATATATG ATGTATTTTC CACAGATGTT TCATGATTTC CAGTTTTCAT 400 CGTGTCTTTT TTTTCCTTGT AGGCAAATGT GCAATACCAA CATGTCTGTA 450 CCTACTGATG GGGCTGTAAC CACCCCACAG ATTCCAGCTT CGGAACAAGA 500 20 base pairs Nucleic Acid Single Linear Yes not provided 3 CAGCCAAGCT CGCGCGGTGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 4 TCTTTCCGAC ACACAGGGCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 5 CAGCAGGATC TCGGTCAGAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 6 GGGCGCTCGT ACGCACTAAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 7 TCGGGGATCA TTCCACTCTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 8 CGGGGTTTTC GCGCTTGGAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 9 CATTTGCCTG CTCCTCACCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 10 GTATTGCACA TTTGCCTGCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 11 AGCACCATCA GTAGGTACAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 12 CTACCAAGTT CCTGTAGATC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 13 TCAACTTCAA ATTCTACACT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 14 TTTACAATCA GGAACATCAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 15 AGCTTCTTTG CACATGTAAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 16 CAGGTCAACT AGGGGAAATA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 17 TCTTATAGAC AGGTCAACTA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 18 TCCTAGGGTT ATATAGTTAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 19 AAGTATTCAC TATTCCACTA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 20 CCAAGATCAC CCACTGCACT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 21 AGGTGTGGTG GCAGATGACT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 22 CCTGTCTCTA CTAAAAGTAC 20 20 base pairs Nucleic Acid Single Linear No not provided 23 ACAAGCCTTC GCTCTACCGG 20 20 base pairs Nucleic Acid Single Linear No not provided 24 TTCAGCGCAT TTGTACATAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 25 TCTTTCCGAC ACACAGGGCC 20 20 base pairs Nucleic Acid Single Linear No not provided 26 AGCTTCTTTA TACATGTAAA 20 20 base pairs Nucleic Acid Single Linear No not provided 27 AGCTTCTTTA CACATGTAAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 28 CTACCCTCCA ATCGCCACTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 29 GGTCTACCCT CCAATCGCCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 30 CGTGCCCACA GGTCTACCCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 31 AAGTGGCGTG CGTCCGTGCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 32 AAAGTGGCGT GCGTCCGTGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 33 AAGCAGCCAA GCTCGCGCGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 34 CAGGCCCCAG AAGCAGCCAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 35 GCCACACAGG CCCCAGAAGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 36 ACACACAGGG CCACACAGGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 37 TTCCGACACA CAGGGCCACA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 38 GCTCCATCTT TCCGACACAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 39 GCTTCTTGCT CCATCTTTCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 40 CCCTCGGGCT CGGCTTCTTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 41 GCGGCCGCCC CTCGGGCTCG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 42 AAGCAGCAGG ATCTCGGTCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 43 GCTGCGAAAG CAGCAGGATC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 44 TGCTCCTGGC TGCGAAAGCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 45 GGGACGGTGC TCCTGGCTGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 46 ACTGGGCGCT CGTACGCACT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 47 GCCAGGGCAC TGGGCGCTCG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 48 TCTCCGGGCC AGGGCACTGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 49 TCATTCCACT CTCCGGGCCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 50 GGAAGCACGA CGCCCTGGGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 51 TACTGCGGAA GCACGACGCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 52 GGGACTGACT ACTGCGGAAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 53 TCAAGACTCC CCAGTTTCCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 54 CCTGCTCCTC ACCATCCGGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 55 TTTGCCTGCT CCTCACCATC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 56 ATTTGCCTGC TCCTCACCAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 57 ACATTTGCCT GCTCCTCACC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 58 CACATTTGCC TGCTCCTCAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 59 GCACATTTGC CTGCTCCTCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 60 TGCACATTTG CCTGCTCCTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 61 TTGCACATTT GCCTGCTCCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 62 ATTGCACATT TGCCTGCTCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 63 TATTGCACAT TTGCCTGCTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 64 GGTATTGCAC ATTTGCCTGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 65 TGGTATTGCA CATTTGCCTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 66 TTGGTATTGC ACATTTGCCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 67 GTTGGTATTG CACATTTGCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 68 TGTTGGTATT GCACATTTGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 69 ATGTTGGTAT TGCACATTTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 70 CATGTTGGTA TTGCACATTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 71 ACATGTTGGT ATTGCACATT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 72 GACATGTTGG TATTGCACAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 73 AGACATGTTG GTATTGCACA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 74 CAGACATGTT GGTATTGCAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 75 CAGTAGGTAC AGACATGTTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 76 TACAGCACCA TCAGTAGGTA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 77 GGAATCTGTG AGGTGGTTAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 78 TTCCGAAGCT GGAATCTGTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 79 AGGGTCTCTT GTTCCGAAGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 80 GCTTTGGTCT AACCAGGGTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 81 GCAATGGCTT TGGTCTAACC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 82 TAACTTCAAA AGCAATGGCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 83 GTGCACCAAC AGACTTTAAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 84 ACCTCTTTCA TAGTATAAGT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 85 ATAATATACT GGCCAAGATA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 86 TAATCGTTTA GTCATAATAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 87 ATCATATAAT CGTTTAGTCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 88 GCTTCTCATC ATATAATCGT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 89 CAATATGTTG TTGCTTCTCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 90 GAACAATATA CAATATGTTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 91 TCATTTGAAC AATATACAAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 92 TAGAAGATCA TTTGAACAAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 93 AACAAATCTC CTAGAAGATC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 94 TGGCACGCCA AACAAATCTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 95 AGAAGCTTGG CACGCCAAAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 96 CTTTCACAGA GAAGCTTGGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 97 TTTTCCTGTG CTCTTTCACA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 98 TATATATTTT CCTGTGCTCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 99 ATCATGGTAT ATATTTTCCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 100 TTCCTGTAGA TCATGGTATA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 101 TACTACCAAG TTCCTGTAGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 102 TTCCTGCTGA TTGACTACTA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 103 TGAGTCCGAT GATTCCTGCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 104 CAGATGTACC TGAGTCCGAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 105 CTGTTCTCAC TCACAGATGT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 106 TTCAAGGTGA CACCTGTTCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 107 ACTCCCACCT TCAAGGTGAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 108 GGTCCTTTTG ATCACTCCCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 109 AAGCTCTTGT ACAAGGTCCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 110 CTCTTCCTGA AGCTCTTGTA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 111 AAGATGAAGG TTTCTCTTCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 112 AAACCAAATG TGAAGATGAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 113 ATGGTCTAGA AACCAAATGT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 114 CTAGATGAGG TAGATGGTCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 115 AATTGCTCTC CTTCTAGATG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 116 TCTGTCTCAC TAATTGCTCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 117 TCTGAATTTT CTTCTGTCTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 118 CACCAGATAA TTCATCTGAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 119 TTTGTCGTTC ACCAGATAAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 120 GTGGCGTTTT CTTTGTCGTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 121 TACTATCAGA TTTGTGGCGT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 122 GAAAGGGAAA TACTATCAGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 123 GCTTTCATCA AAGGAAAGGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 124 TACACACAGA GCCAGGCTTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 125 CTCCCTTATT ACACACAGAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 126 TCACAACATA TCTCCCTTAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 127 CTACTGCTTC TTTCACAACA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 128 GATTCACTGC TACTGCTTCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 129 TGGCGTCCCT GTAGATTCAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 130 AAGATCCGGA TTCGATGGCG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 131 CAGCATCAAG ATCCGGATTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 132 GTTCACTTAC ACCAGCATCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 133 CAATCACCTG AATGTTCACT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 134 CTGATCCAAC CAATCACCTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 135 GAAACTGAAT CCTGATCCAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 136 TGATCTGAAA CTGAATCCTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 137 CTACACTAAA CTGATCTGAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 138 CAACTTCAAA TTCTACACTA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 139 AGATTCAACT TCAAATTCTA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 140 GAGTCGAGAG ATTCAACTTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 141 TAATCTTCTG AGTCGAGAGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 142 CTAAGGCTAT AATCTTCTGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 143 TTCTTCACTA AGGCTATAAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 144 TCTTGTCCTT CTTCACTAAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 145 CTGAGAGTTC TTGTCCTTCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 146 TTCATCTGAG AGTTCTTGTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 147 CCTCATCATC TTCATCTGAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 148 CTTGATATAC CTCATCATCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 149 ATACACAGTA ACTTGATATA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 150 CTCTCCCCTG CCTGATACAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 151 GAATCTGTAT CACTCTCCCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 152 TCTTCAAATG AATCTGTATC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 153 AAATTTCAGG ATCTTCTTCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 154 AGTCAGCTAA GGAAATTTCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 155 GCATTTCCAA TAGTCAGCTA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 156 CATTGCATGA AGTGCATTTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 157 TCATTTCATT GCATGAAGTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 158 CATCTGTTGC AATGTGATGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 159 GAAGGGCCCA ACATCTGTTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 160 TTCTCACGAA GGGCCCAACA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 161 GAAGCCAATT CTCACGAAGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 162 TATCTTCAGG AAGCCAATTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 163 CTTTCCCTTT ATCTTCAGGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 164 TCCCCTTTAT CTTTCCCTTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 165 CTTTCTCAGA GATTTCCCCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 166 CAGTTTGGCT TTCTCAGAGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 167 GTGTTGAGTT TTCCAGTTTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 168 CCTCTTCAGC TTGTGTTGAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 169 ACATCAAAGC CCTCTTCAGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 170 GAATCATTCA CTATAGTTTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 171 ATGACTCTCT GGAATCATTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 172 CCTCAACACA TGACTCTCTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 173 TTATCATCAT TTTCCTCAAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 174 TAATTTTATC ATCATTTTCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 175 GAAGCTTGTG TAATTTTATC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 176 TGATTGTGAA GCTTGTGTAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 177 CACTTTCTTG TGATTGTGAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 178 GCTGAGAATA GTCTTCACTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 179 AGTTGATGGC TGAGAATAGT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 180 TGCTACTAGA AGTTGATGGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 181 TAAATAATGC TACTAGAAGT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 182 CTTGGCTGCT ATAAATAATG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 183 ATCTTCTTGG CTGCTATAAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 184 AACTCTTTCA CATCTTCTTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 185 CCCTTTCAAA CTCTTTCACA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 186 GGGTTTCTTC CCTTTCAAAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 187 TCTTTGTCTT GGGTTTCTTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 188 CTCTCTTCTT TGTCTTGGGT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 189 AACTAGATTC CACACTCTCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 190 CAAGGTTCAA TGGCATTAAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 191 TGACAAATCA CACAAGGTTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 192 TCGACCTTGA CAAATCACAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 193 ATGGACAATG CAACCATTTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 194 TGTTTTGCCA TGGACAATGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 195 TAAGATGTCC TGTTTTGCCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 196 GCAGGCCATA AGATGTCCTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 197 ACATGTAAAG CAGGCCATAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 198 CTTTGCACAT GTAAAGCAGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 199 TTTCTTTAGC TTCTTTGCAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 200 TTATTCCTTT TCTTTAGCTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 201 TGGGCAGGGC TTATTCCTTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 202 ACATACTGGG CAGGGCTTAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 203 TTGGTTGTCT ACATACTGGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 204 TCATTTGAAT TGGTTGTCTA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 205 AAGTTAGCAC AATCATTTGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 206 TCTCTTATAG ACAGGTCAAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 207 AAATATATAA TTCTCTTATA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 208 AGTTAGAAAT ATATAATTCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 209 ATATAGTTAG AAATATATAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 210 CTAGGGTTAT ATAGTTAGAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 211 TAAATTCCTA GGGTTATATA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 212 CAGGTTGTCT AAATTCCTAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 213 ATAAATTTCA GGTTGTCTAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 214 ATATATGTGA ATAAATTTCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 215 CTTTGATATA TGTGAATAAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 216 CATTTTCTCA CTTTGATATA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 217 ATTGAGGCAT TTTCTCACTT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 218 AATCTATGTG AATTGAGGCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 219 AGAAGAAATC TATGTGAATT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 220 ATACTAAAGA GAAGAAATCT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 221 GTCAATTATA CTAAAGAGAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 222 TAGGTCAATT ATACTAAAGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 223 CAAAGTAGGT CAATTATACT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 224 CCACTACCAA AGTAGGTCAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 225 AGTATTCACT ATTCCACTAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 226 TATAGTAAGT ATTCACTATT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 227 AGTCAAATTA TAGTAAGTAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 228 CATATTCAAG TCAAATTATA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 229 AAAGGATGAG CTACATATTC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 230 GTGTAAAGGA TGAGCTACAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 231 TAGGAGTTGG TGTAAAGGAT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 232 TTTAAAATTA GGAGTTGGTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 233 GAAATTATTT AAAATTAGGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 234 CAGAGTAGAA ATTATTTAAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 235 CTCATTTAAG ACAGAGTAGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 236 TACTTCTCAT TTAAGACAGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 237 CATATACATA TTTAAGAAAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 238 TTAAATGTCA TATACATATT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 239 TAATAAGTTA CATTTAAATG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 240 GTAACAGAGC AAGACTCGGT 20 20 base pairs Nucleic Acid Single Linear Yes not provided 241 CAGCCTGGGT AACAGAGCAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 242 CACTCCAGCC TGGGTAACAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 243 CCCACTGCAC TCCAGCCTGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 244 GCCAAGATCA CCCACTGCAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 245 GCAGTGAGCC AAGATCACCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 246 GAGCTTGCAG TGAGCCAAGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 247 GAGGGCAGAG CTTGCAGTGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 248 CAGGAGAATG GTGCGAACCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 249 AGGCTGAGGC AGGAGAATGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 250 ATTGGGAGGC TGAGGCAGGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 251 CAAGCTAATT GGGAGGCTGA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 252 AGGCCAAGCT AATTGGGAGG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 253 ATGACTGTAG GCCAAGCTAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 254 CAGATGACTG TAGGCCAAGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 255 GGTGGCAGAT GACTGTAGGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 256 AATTAGCCAG GTGTGGTGGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 257 GTCTCTACTA AAAGTACAAA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 258 CGGTGAAACC CTGTCTCTAC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 259 TGGCTAACAC GGTGAAACCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 260 AGACCATCCT GGCTAACACG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 261 GAGATCGAGA CCATCCTGGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 262 GAGGTCAGGA GATCGAGACC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 263 GCGGATCACG AGGTCAGGAG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 264 AGGCCGAGGT GGGCGGATCA 20 20 base pairs Nucleic Acid Single Linear Yes not provided 265 TTTGGGAGGC CGAGGTGGGC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 266 TCCCAGCACT TTGGGAGGCC 20 20 base pairs Nucleic Acid Single Linear Yes not provided 267 CCTGTAATCC CAGCACTTTG 20 20 base pairs Nucleic Acid Single Linear Yes not provided 268 GTGGCTCATG CCTGTAATCC 20 21 base pairs Nucleic Acid Single Linear Yes not provided 269 GGCAAATGTG CAATACCAAC A 21 26 base pairs Nucleic Acid Single Linear Yes not provided 270 TGCACCAACA GACTTTAATA ACTTCA 26 25 base pairs Nucleic Acid Single Linear Yes not provided 271 CCACCTCACA GATTCCAGCT TCGGA 25

Claims

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to the 5′ untranslated region, translation termination codon region or 3′ untranslated region of a nucleic acid molecule encoding human mdm2, wherein said antisense compound modulates the expression of human mdm2.

2. The antisense compound of

claim 1

wherein said antisense compound inhibits the expression of human mdm2.

3. The antisense compound of

claim 1

which is an antisense oligonucleotide.

4. An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 36, SEQ ID NO: 52, SEQ ID NO: 216, SEQ ID NO: 246, SEQ ID NO: 251, SEQ ID NO: 260, or SEQ ID NO: 264 which inhibits the expression of human mdm2.

5. The antisense compound of

claim 2

which is targeted to the 5′ untranslated region of the S-mdm2 transcript.

6. The antisense compound of

claim 5

comprising SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 7.

7. The antisense compound of

claim 2

comprising SEQ ID NO: 4.

8. The antisense compound of

claim 1

which contains at least one phosphorothioate intersugar linkage.

9. The antisense compound of

claim 1

which has at least one 2′-O-methoxyethyl modification.

10. The antisense compound of

claim 1

which contains at least one 5-methyl cytidine.

11. The antisense compound of

claim 10

in which every 2′-O-methoxyethyl modified cytidine residue is a 5-methyl cytidine.

12. A pharmaceutical composition comprising the antisense compound of

claim 1

and a pharmaceutically acceptable carrier or diluent.

13. The pharmaceutical composition of

claim 12

wherein said pharmaceutically acceptable carrier or diluent further comprises a lipid or liposome.

14. A method of modulating the expression of human mdm2 in cells or tissues comprising contacting said cells or tissues with the antisense compound of

claim 1

.

15. A method of reducing hyperproliferation of human cells comprising contacting proliferating human cells with the antisense compound of

claim 2

or a pharmaceutical composition comprising said antisense compound.

16. A method of treating an animal having a disease or condition associated with mdm2 comprising administering to said animal a therapeutically or prophylactically effective amount of an antisense compound of

claim 1

.

17. The method of

claim 16

wherein the disease or condition is associated with overexpression of mdm2 and the antisense compound inhibits the expression of mdm2.

18. The method of

claim 16

wherein the disease or condition is associated with amplification of the mdm2 gene and the antisense compound inhibits the expression of mdm2.

19. The method of

claim 16

wherein the disease or condition is a hyperproliferative condition and the antisense compound inhibits the expression of mdm2.

20. The method of

claim 19

wherein the hyperproliferative condition is cancer.

21. The method of

claim 20

wherein the cancer is a blood, brain, breast, lung or a soft tissue cancer.

22. The method of

claim 19

wherein the hyperproliferative condition is psoriasis, fibrosis, atherosclerosis or restenosis.

23. The method of

claim 16

wherein said antisense compound is administered in combination with a chemotherapeutic agent to overcome drug resistance.

24. An antisense compound up to 30 nucleobases in length targeted to the coding region or translational start site of a nucleic acid molecule encoding human mdm2, wherein said antisense compound inhibits the expression of said human mdm2 and comprises at least an 8-nucleobase portion of SEQ ID NO: 15, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 120, SEQ ID NO: 126, SEQ ID NO: 160, SEQ ID NO: 177, SEQ ID NO: 180, or SEQ ID NO: 195.

25. The antisense compound of

claim 24

which contains at least one phosphorothioate intersugar linkage.

26. The antisense compound of

claim 24

which has at least one 2′-O-methoxyethyl modification.

27. The antisense compound of

claim 24

which contains at least one 5-methyl cytidine.

28. The antisense compound of

claim 27

29. A pharmaceutical composition comprising the antisense compound of

claim 24

and a pharmaceutically acceptable carrier or diluent.

30. The pharmaceutical composition of

claim 29

wherein said pharmaceutically acceptable carrier or diluent comprises a lipid or liposome.

31. A method of modulating the expression of human mdm2 in cells or tissues comprising contacting said cells or tissues with the antisense compound of

claim 24

.

32. A method of reducing hyperproliferation of human cells comprising contacting proliferating human cells with the antisense compound of

claim 24

.

33. A method of reducing hyperproliferation of human cells comprising contacting proliferating human cells with the pharmaceutical composition of

claim 29

.

34. A method of treating an animal having a disease or condition associated with mdm2 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of

claim 24

.

35. The method of

claim 34

36. The method of

claim 34

37. The method of

claim 34

38. The method of

claim 37

wherein the hyperproliferative condition is cancer.

39. The method of

claim 38

wherein the cancer is a blood, brain, breast, lung or a soft tissue cancer.

40. The method of

claim 37

41. The method of

claim 34